Bonaventura Clotet | Academic Influence

Bonaventura Clotet's AcademicInfluence.com Rankings

Bonaventura Clotet

Philosophy

#4633

World Rank

#7224

Historical Rank

Logic

#2052

World Rank

#2949

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Bonaventura Clotet's Degrees

Bachelors Medicine University of Barcelona
Doctorate Medicine University of Barcelona

Why Is Bonaventura Clotet Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Bonaventura Clotet Sala is a Spanish physician. He has been the head of the HIV unit at the Germans Trias i Pujol University Hospital in Badalona from 1987 to 2015, and since then he has been the head of the Infectious Diseases service at the same hospital. He has been the director of the IrsiCaixa AIDS Research Institute since 1995 and chairman of the Fight Against AIDS Foundation since 1992. Since 2006 he has been co-director of the HIVACAT AIDS vaccine research program. He has been an associate professor at the Autonomous University of Barcelona since 1986 and director of the Chair in AIDS and Related Diseases at the University of Vic , since October 2013.

(See a Problem?)

Bonaventura Clotet's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Update of the Drug Resistance Mutations in HIV-1. (2008) (2026)
Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. (2016) (1072)
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. (2000) (917)
Maraviroc for previously treated patients with R5 HIV-1 infection. (2008) (744)
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. (2003) (652)
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. (1998) (593)
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. (2003) (575)
Raltegravir with optimized background therapy for resistant HIV-1 infection. (2008) (570)
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. (2008) (569)
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects (2010) (564)
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. (2008) (544)
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials (2007) (470)
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study (2014) (426)
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial (2011) (362)
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. (2011) (361)
Clinical utility of HIV-1 genotyping and expert advice: the Havana trial (2002) (358)
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial (2017) (339)
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years (2007) (336)
Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study (2020) (308)
Gut Microbiota Linked to Sexual Preference and HIV Infection (2016) (302)
Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile (2001) (289)
Drug resistance mutations in HIV-1. (2003) (280)
Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study (2012) (273)
Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. (2000) (267)
Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1-positive patients. (2006) (262)
Prospective Randomized Two‐Arm Controlled Study To Determine the Efficacy of a Specific Intervention To Improve Long‐Term Adherence to Highly Active Antiretroviral Therapy (2000) (262)
Transmission of drug-resistant HIV-1 is stabilizing in Europe. (2009) (259)
Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication (2002) (259)
European guidelines on the clinical management of HIV-1 tropism testing. (2011) (256)
Update of the drug resistance mutations in HIV-1: Fall 2005. (2005) (254)
Update of the drug resistance mutations in HIV-1: Fall 2006. (2006) (250)
Update of the drug resistance mutations in HIV-1: December 2010. (2010) (234)
Update of the drug resistance mutations in HIV-1: December 2009. (2008) (231)
Capture and transfer of HIV-1 particles by mature dendritic cells converges with the exosome-dissemination pathway. (2009) (219)
Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression (2000) (219)
Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial (2020) (219)
Siglec-1 Is a Novel Dendritic Cell Receptor That Mediates HIV-1 Trans-Infection Through Recognition of Viral Membrane Gangliosides (2012) (213)
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. (2000) (207)
A Dendritic Cell–Based Vaccine Elicits T Cell Responses Associated with Control of HIV-1 Replication (2013) (206)
Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. (1998) (204)
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. (2010) (200)
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients (2003) (190)
Use of antiviral drugs to reduce COVID-19 transmission (2020) (188)
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial (2007) (188)
Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. (2015) (185)
Update of the drug resistance mutations in HIV-1: 2007. (2007) (183)
Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. (2002) (183)
Long-Term Neuropsychiatric Disorders on Efavirenz-Based Approaches: Quality of Life, Psychologic Issues, and Adherence (2005) (182)
A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. (2003) (177)
Secretion of interferon‐γ by human macrophages demonstrated at the single‐cell level after costimulation with interleukin (IL)‐12 plus IL‐18 (2009) (170)
High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study (2010) (165)
Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients: Pooled Results From the Phase 3 Double-Blind Randomized ECHO and THRIVE Trials (2012) (165)
Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies: 48-Week Analysis (2012) (163)
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. (2012) (162)
Update of the Drug Resistance Mutations in HIV-1: 2005. (2005) (160)
Prevalence of genotypic resistance to nucleoside analogues in antiretroviral‐naive and antiretroviral‐experienced HIV‐infected patients in Spain (1998) (159)
HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection (2001) (159)
Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? (2005) (159)
Definition of the viral targets of protective HIV-1-specific T cell responses (2011) (157)
A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19 (2020) (156)
Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials (2005) (156)
Quality of Life, Emotional Status, and Adherence of HIV‐1‐Infected Patients Treated With Efavirenz Versus Protease Inhibitor‐Containing Regimens (2002) (151)
Interleukin-7 in Plasma Correlates with CD4 T-Cell Depletion and May Be Associated with Emergence of Syncytium-Inducing Variants in Human Immunodeficiency Virus Type 1-Positive Individuals (2001) (144)
Update of the drug resistance mutations in HIV-1: Spring 2008. (2008) (142)
Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins (2006) (139)
Visceral leishmaniasis in patients infected with human immunodeficiency virus. Co-operative Group for the Study of Leishmaniasis in AIDS. (1990) (138)
HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics (2013) (136)
A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. (2009) (134)
Detection of SARS-CoV-2 in a cat owned by a COVID-19−affected patient in Spain (2020) (133)
Sexual transmission of hepatitis C virus and its relation with hepatitis B virus and HIV. (1990) (133)
Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load (2004) (130)
Cell Cycle Control and HIV-1 Susceptibility Are Linked by CDK6-Dependent CDK2 Phosphorylation of SAMHD1 in Myeloid and Lymphoid Cells (2014) (129)
Transport of Lamivudine [(-)-β-l-2′,3′-Dideoxy-3′-thiacytidine] and High-Affinity Interaction of Nucleoside Reverse Transcriptase Inhibitors with Human Organic Cation Transporters 1, 2, and 3 (2009) (128)
CTL Responses of High Functional Avidity and Broad Variant Cross-Reactivity Are Associated with HIV Control (2012) (127)
Treatment Intensification with Raltegravir in Subjects with Sustained HIV-1 Viraemia Suppression: A Randomized 48-Week Study (2012) (125)
CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART (2010) (125)
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. (2013) (125)
Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity (2002) (123)
Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications. (2010) (121)
Antiretroviral Treatment Simplification With Nevirapine in Protease Inhibitor‐Experienced Patients With HIV‐Associated Lipodystrophy: 1‐Year Prospective Follow‐Up of a Multicenter, Randomized, Controlled Study (2001) (120)
Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine (2002) (120)
A therapeutic dendritic cell-based vaccine for HIV-1 infection. (2011) (116)
Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir). (1998) (116)
Shift of Clinical Human Immunodeficiency Virus Type 1 Isolates from X4 to R5 and Prevention of Emergence of the Syncytium-Inducing Phenotype by Blockade of CXCR4 (1999) (114)
Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co‐infected patients (2003) (114)
Natural History of Human Papillomavirus Infections Involving Anal, Penile, and Oral Sites Among HIV-Positive Men (2013) (114)
Update of the drug resistance mutations in HIV-1: 2004. (2004) (110)
Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538) (1996) (110)
Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with </=250/microL CD4 T cells and undetectable plasma virus load. (1999) (109)
High Level of Coreceptor-independent HIV Transfer Induced by Contacts between Primary CD4 T Cells* (2004) (108)
Virological rebound after suppression on highly active antiretroviral therapy (2003) (108)
Drug resistance mutations in HIV-1. (2003) (108)
EOSINOPHILIC PUSTULAR FOLLICULITIS IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME (1992) (106)
Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials (2010) (106)
Prevalence and Characteristics of Multinucleoside-Resistant Human Immunodeficiency Virus Type 1 among European Patients Receiving Combinations of Nucleoside Analogues (2000) (105)
Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen (2007) (104)
IL28B SNP rs8099917 Is Strongly Associated with Pegylated Interferon-α and Ribavirin Therapy Treatment Failure in HCV/HIV-1 Coinfected Patients (2010) (103)
Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions (2002) (103)
Measurement of Intracellular Didanosine and Tenofovir Phosphorylated Metabolites and Possible Interaction of the Two Drugs in Human Immunodeficiency Virus-Infected Patients (2005) (102)
Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus (2006) (102)
Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance. (2001) (101)
Maturation of Blood-Derived Dendritic Cells Enhances Human Immunodeficiency Virus Type 1 Capture and Transmission (2007) (101)
Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen (2000) (99)
Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. (2008) (98)
Efficacy and Safety of Switching From Boosted Lopinavir to Boosted Atazanavir in Patients With Virological Suppression Receiving a LPV/r-Containing HAART: The ATAZIP Study (2009) (98)
Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients. (1999) (97)
Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor. (1999) (97)
Lymphogranuloma venereum proctocolitis: a silent endemic disease in men who have sex with men in industrialised countries (2010) (96)
Clinical management of HIV-1 resistance. (2010) (95)
Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients (2007) (95)
The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial. (2015) (94)
Multiple dideoxynucleoside analogue‐resistant (MddNR) HIV‐1 strains isolated from patients from different European countries (1998) (92)
Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452) (2008) (92)
Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. (2001) (90)
Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine (2005) (90)
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DU (2017) (90)
A Simplification Trial Switching From Nucleoside Reverse Transcriptase Inhibitors to Once-Daily Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1-Infected Patients With Virological Suppression (2009) (88)
The implication of the chemokine receptor CXCR4 in HIV-1 envelope protein-induced apoptosis is independent of the G protein-mediated signalling. (1999) (87)
Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial. (2014) (87)
Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients (2001) (86)
Safety of Enfuvirtide in Combination With an Optimized Background of Antiretrovirals in Treatment-Experienced HIV-1-Infected Adults Over 48 Weeks (2005) (85)
Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations (2004) (85)
Aging in HIV-Infected Subjects: A New Scenario and a New View (2017) (84)
Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study. (2003) (82)
RNA interference of HIV replication. (2002) (81)
Sequence Homology Required by Human Immunodeficiency Virus Type 1 To Escape from Short Interfering RNAs (2006) (81)
Antigp41 antibodies fail to block early events of virological synapses but inhibit HIV spread between T cells (2009) (80)
Thymidine Analogue Mutation Profiles: Factors Associated with Acquiring Specific Profiles and their Impact on the Virological Response to Therapy (2005) (80)
Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain (2000) (80)
Screening NK-, B- and T-cell phenotype and function in patients suffering from Chronic Fatigue Syndrome (2013) (79)
Leishmaniasis in HIV infection. (2003) (79)
Cell-surface-expressed HIV-1 envelope induces the death of CD4 T cells during GP41-mediated hemifusion-like events. (2003) (78)
Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review. (2009) (78)
Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine (1994) (78)
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. (2008) (77)
A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques (2015) (77)
Laboratory Guidelines for the Practical Use of HIV Drug Resistance Tests in Patient Follow-Up (2001) (75)
Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. (2003) (75)
Effectiveness of Mindfulness-Based Cognitive Therapy on the Quality of Life, Emotional Status, and CD4 Cell Count of Patients Aging with HIV Infection (2013) (74)
Changes in codon-pair bias of human immunodeficiency virus type 1 have profound effects on virus replication in cell culture (2013) (74)
Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts * (2008) (74)
Pilot Pharmacokinetic Study of Human Immunodeficiency Virus-Infected Patients Receiving Tenofovir Disoproxil Fumarate (TDF): Investigation of Systemic and Intracellular Interactions between TDF and Abacavir, Lamivudine, or Lopinavir-Ritonavir (2009) (74)
Reversal of HIV-1-associated osteoporosis with once-weekly alendronate (2005) (73)
A clathrin-dynamin-dependent endocytic pathway for the uptake of HIV-1 by direct T cell-T cell transmission. (2008) (73)
Cerebrospinal fluid HIV-1 RNA levels in asymptomatic patients with early stage chronic HIV-1 infection: support for the hypothesis of local virus replication. (1999) (73)
Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort (2018) (73)
Analytical and clinical performance of the panbio COVID-19 antigen-detecting rapid diagnostic test (2020) (73)
Expression and Functionality of Anti-Human Immunodeficiency Virus and Anticancer Drug Uptake Transporters in Immune Cells (2008) (73)
CXCR4 and SDF-1 expression in B-cell chronic lymphocytic leukemia and stage of the disease (2003) (72)
Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression (2009) (72)
Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz. (2008) (72)
A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. (1998) (72)
Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations (2004) (72)
High prevalence of human papillomavirus infection in the anus, penis and mouth in HIV-positive men (2006) (71)
Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. (2002) (71)
Clinically Validated Genotype Analysis: Guiding Principles and Statistical Concerns (2004) (70)
Frequent hepatitis B virus rebound among HIV–hepatitis B virus-coinfected patients following antiretroviral therapy interruption (2010) (70)
Drug uptake transporters in antiretroviral therapy. (2011) (70)
HIV-1 resistance to the gp41-dependent fusion inhibitor C-34. (2003) (69)
Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. (1999) (68)
Effect of Baseline CD4 Cell Count on the Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Patients With HIV/Hepatitis C Virus Coinfection (2008) (68)
SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity (2021) (67)
Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity (2020) (67)
[Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004)]. (2004) (67)
Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection (2014) (66)
Steady-State Pharmacokinetics of a Double-Boosting Regimen of Saquinavir Soft Gel plus Lopinavir plus Minidose Ritonavir in Human Immunodeficiency Virus-Infected Adults (2004) (66)
Viral Dynamics during Structured Treatment Interruptions of Chronic Human Immunodeficiency Virus Type 1 Infection (2002) (65)
Primary resistance to integrase strand-transfer inhibitors in Europe. (2015) (65)
The CXCR4 Antagonist AMD3100 Efficiently Inhibits Cell-Surface-Expressed Human Immunodeficiency Virus Type 1 Envelope-Induced Apoptosis (2000) (64)
Deep Molecular Characterization of HIV-1 Dynamics under Suppressive HAART (2011) (64)
Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el virus de la inmunodeficiencia humana en el año 2002 (2002) (63)
Evaluation of the anti-HIV activity of statins (2005) (63)
Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes (2021) (62)
Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients (2004) (61)
Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches (2003) (61)
The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial (2000) (61)
HIV-1 Protease Catalytic Efficiency Effects Caused by Random Single Amino Acid Substitutions (2006) (60)
Changes in the rate of genotypic resistance to antiretroviral drugs in Spain. (2001) (60)
Monitoring adherence to HIV therapy. (1999) (60)
HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro (2008) (60)
Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia. (1999) (60)
M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. (2002) (59)
Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial (2021) (59)
Impact of Nevirapine on Lipid Metabolism (2003) (59)
Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study) (2017) (59)
Assessing self-reported adherence to HIV therapy by questionnaire: the SERAD (Self-Reported Adherence) Study. (2007) (59)
Evolution of the gut microbiome following acute HIV-1 infection (2019) (59)
Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment. (2012) (58)
Rhodococcus equi infection in HIV-infected patients. (1993) (58)
Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C. (2011) (58)
R5 HIV gp120‐mediated cellular contacts induce the death of single CCR5‐expressing CD4 T cells by a gp41‐dependent mechanism (2004) (57)
Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure. (2010) (57)
Restriction of HIV-1 Replication in Primary Macrophages by IL-12 and IL-18 through the Upregulation of SAMHD1 (2013) (57)
Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy. (2004) (57)
A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study. (1999) (56)
p21 regulates the HIV-1 restriction factor SAMHD1 (2014) (56)
Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection: The Phase 2 DURVAST Study. (2020) (56)
Immunodiscordant responses to HAART – mechanisms and consequences (2013) (55)
Determinants of virological failure and antiretroviral drug resistance in Mozambique. (2015) (55)
Treatment of monocytes with interleukin (IL)‐12 plus IL‐18 stimulates survival, differentiation and the production of CXC chemokine ligands (CXCL)8, CXCL9 and CXCL10 (2006) (55)
Prevalence, Clearance, and Incidence of Human Papillomavirus Type–Specific Infection at the Anal and Penile Site of HIV-Infected Men (2013) (55)
Transmitted Drug Resistant HIV-1 and Association With Virologic and CD4 Cell Count Response to Combination Antiretroviral Therapy in the EuroSIDA Study (2008) (55)
Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. (2015) (54)
Detection of a sexually transmitted hepatitis C virus protease inhibitor-resistance variant in a human immunodeficiency virus-infected homosexual man. (2014) (54)
CD32 expression is associated to T-cell activation and is not a marker of the HIV-1 reservoir (2018) (54)
Added Value of Deep Sequencing Relative to Population Sequencing in Heavily Pre-Treated HIV-1-Infected Subjects (2011) (53)
HIV transfer between CD4 T cells does not require LFA-1 binding to ICAM-1 and is governed by the interaction of HIV envelope glycoprotein with CD4 (2008) (53)
Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial (2016) (53)
Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings. (2009) (53)
Safety and Efficacy of Once-Daily Didanosine, Tenofovir and Nevirapine as a Simplification Antiretroviral Approach (2003) (53)
ZNRD1 (zinc ribbon domain-containing 1) is a host cellular factor that influences HIV-1 replication and disease progression. (2010) (52)
Reconstructive treatment for antiretroviral-associated facial lipoatrophy: a prospective study comparing autologous fat and synthetic substances. (2006) (52)
CCR5 Δ32 homozygous cord blood allogeneic transplantation in a patient with HIV: a case report. (2015) (52)
Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO (2014) (51)
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. (2007) (51)
Response to Antiretroviral Therapy among Patients Exposed to Three Classes of Antiretrovirals: Results from the Eurosida Study (2002) (51)
Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA (2008) (51)
Musculoskeletal manifestations in patients positive for human immunodeficiency virus: correlation with CD4 count. (2001) (51)
Mechanisms That Contribute to a Profound Reduction of the HIV-1 Reservoir After Allogeneic Stem Cell Transplant (2018) (51)
Fitness Landscape of Human Immunodeficiency Virus Type 1 Protease Quasispecies (2007) (50)
Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy (2011) (50)
Distribution of Human Papillomavirus Genotypes in Anal Cytological and Histological Specimens from HIV-Infected Men Who Have Sex with Men and Men Who Have Sex with Women (2013) (50)
Performance characteristics of five antigen-detecting rapid diagnostic test (Ag-RDT) for SARS-CoV-2 asymptomatic infection: a head-to-head benchmark comparison (2021) (49)
Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery (2012) (49)
Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients. (2006) (49)
Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial (2018) (48)
High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy. (2012) (48)
New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors. (2012) (48)
Simultaneous Population Pharmacokinetic Model for Lopinavir and Ritonavir in HIV-Infected Adults (2008) (48)
Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA). (2009) (47)
Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infection (2018) (47)
Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen (2006) (47)
Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study. (2018) (47)
Effect of the interleukin‐6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients (2007) (46)
Anti-HIV Activity and Resistance Profile of the CXC Chemokine Receptor 4 Antagonist POL3026 (2008) (46)
Características clinicoepidemiológicas y tendencias en el tratamiento antirretroviral de una cohorte de pacientes con infección por el virus de la inmunodeficiencia humana. Cohorte PISCIS (2005) (46)
Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el VIH (octubre 2004) (2004) (46)
Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients (2007) (45)
Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study (2008) (45)
Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients (2007) (45)
Insertions in the Reverse Transcriptase Increase both Drug Resistance and Viral Fitness in a Human Immunodeficiency Virus Type 1 Isolate Harboring the Multi-Nucleoside Reverse Transcriptase Inhibitor Resistance 69 Insertion Complex Mutation (2002) (45)
A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy. (2003) (45)
Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection. (2009) (45)
Impact on the immune system of undetectable plasma HIV‐1 RNA for more than 2 years (1998) (44)
Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients (2010) (44)
Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level. (2011) (44)
Antiretroviral Agents Effectively Block HIV Replication after Cell-to-Cell Transfer (2012) (44)
Limited cross-border infections in patients newly diagnosed with HIV in Europe (2013) (44)
Safety, Tolerability, and Efficacy of Darunavir (TMC114) with Low-Dose Ritonavir in Treatment-Experienced, Hepatitis B or C Co-infected Patients in POWER 1 and 3 (2007) (44)
Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe (2014) (44)
Sustained antiretroviral treatment adherence in survivors of the pre-HAART era: attitudes and beliefs (2008) (44)
Visceral leishmaniasis involving lung and a cutaneous Kaposi's sarcoma lesion. (1991) (44)
Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine (2011) (43)
Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215. (2004) (43)
Patterns of Transmitted HIV Drug Resistance in Europe Vary by Risk Group (2014) (43)
Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study). (2014) (43)
Deciphering the Interleukin 28B Variants That Better Predict Response to Pegylated Interferon-α and Ribavirin Therapy in HCV/HIV-1 Coinfected Patients (2012) (43)
A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covid-19 Transmission and Disease (2020) (43)
HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02) (2020) (43)
A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A. (2013) (42)
Lopinavir/Ritonavir Plus Nevirapine as a Nucleoside-Sparing Approach in Antiretroviral-Experienced Patients (NEKA Study) (2005) (42)
GB virus C coinfection in advanced HIV type-1 disease is associated with low CCR5 and CXCR4 surface expression on CD4+ T-cells (2010) (42)
Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations. (1998) (42)
Cell adhesion through alphaV-containing integrins is required for efficient HIV-1 infection in macrophages. (2009) (41)
Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment‐naïve HIV‐1‐infected patients (the ARTEN study) (2011) (41)
Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice. (2006) (41)
Benefits and concerns of simplification strategies in HIV-infected patients. (2006) (41)
Intrahepatic mRNA expression in hepatitis C virus and HIV/hepatitis C virus co-infection: infiltrating cells, cytokines, and influence of HAART (2008) (41)
The anti-HIV activity of ADS-J1 targets the HIV-1 gp120. (2005) (41)
Palbociclib, a selective inhibitor of cyclin-dependent kinase4/6, blocks HIV-1 reverse transcription through the control of sterile &agr; motif and HD domain-containing protein-1 (SAMHD1) activity (2014) (41)
Monitoring Atazanavir Concentrations With Boosted or Unboosted Regimens in HIV-Infected Patients in Routine Clinical Practice (2007) (41)
Alternation of Antiretroviral Drug Regimens for HIV Infection (2003) (41)
Cyclin D3-dependent control of the dNTP pool and HIV-1 replication in human macrophages (2015) (40)
Accuracy of simple biochemical tests in identifying liver fibrosis in patients co-infected with human immunodeficiency virus and hepatitis C virus. (2009) (40)
IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients (2014) (40)
Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection. (2005) (40)
Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study) (2019) (39)
Efficacy of octreotide in the management of chronic diarrhoea in AIDS. (1991) (39)
Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testing. (2014) (39)
On the steps of cell-to-cell HIV transmission between CD4 T cells (2009) (39)
Genetic Variation in IL 28 B and Treatment-induced Clearance of Hepatitis C Virus in HIV-Positive Patients With Acute and Chronic Hepatitis C (2011) (39)
Mouthwashes with CPC Reduce the Infectivity of SARS-CoV-2 Variants In Vitro (2021) (39)
High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial (2022) (39)
[Heterosexual transmission of the human immunodeficiency virus]. (1987) (39)
HIV-1 infected patients older than 50 years. PISCIS cohort study. (2008) (39)
Comparison of gastrointestinal tolerability and patient preference for treatment with the 625 mg and 250 mg nelfinavir tablet formulations (2005) (38)
Prevalence and genotypes of GB virus C/hepatitis G virus (GBV‐C/HGV) and hepatitis C virus among patients infected with human immunodeficiency virus: Evidence of GBV‐C/HGV sexual transmission (1998) (38)
Rate of Virological Treatment Failure and Frequencies of Drug Resistance Genotypes among Human Immunodeficiency Virus-Positive Subjects on Antiretroviral Therapy in Spain (2002) (38)
HIV-1 Subtype Is an Independent Predictor of Reverse Transcriptase Mutation K65R in HIV-1 Patients Treated with Combination Antiretroviral Therapy Including Tenofovir (2012) (38)
Resilience, ageing, and quality of life in long-term diagnosed HIV-infected patients (2015) (38)
A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity. (2011) (38)
Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen (2020) (37)
Long-term effectiveness of infrared coagulation for the treatment of anal intraepithelial neoplasia grades 2 and 3 in HIV-infected men and women (2013) (37)
Influence of human immunodeficiency virus type 1 subtype on mother-to-child transmission. (2003) (37)
Connection Domain Mutations in HIV-1 Reverse Transcriptase Do Not Impact Etravirine Susceptibility and Virologic Responses to Etravirine-Containing Regimens (2011) (37)
Condylomata, cytological abnormalities and human papillomavirus infection in the anal canal in HIV‐infected men (2012) (36)
The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates (2010) (36)
Simultaneous Pharmacogenetics-Based Population Pharmacokinetic Analysis of Darunavir and Ritonavir in HIV-Infected Patients (2013) (36)
Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies. (2005) (35)
Low‐dose interferon alpha combined with zidovudine in patients with AIDS‐associated Kaposi's sarcoma (1993) (35)
Genetic and catalytic efficiency structure of an HCV protease quasispecies (2007) (35)
Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4+ T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral Therapy. (2016) (35)
Psychological stress is associated with high levels of IL-6 in HIV-1 infected individuals on effective combined antiretroviral treatment (2012) (35)
History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change * (2010) (35)
Changes in bloodstream infections in HIV-positive patients in a university hospital in Spain (1995-1997). (2002) (35)
Emergence and genetic evolution of HIV‐1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitors (1999) (35)
Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir. (2000) (35)
Quantitative HIV-1 RNA as a marker of clinical stability and survival in a cohort of 302 patients with a mean CD4 cell count of 300 x 10(6)/l. (1996) (35)
High Prevalence of Sarcopenia in HIV-Infected Individuals (2018) (35)
HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, Spain. (2009) (35)
Immunological and virological study of enfuvirtide-treated HIV-positive patients (2004) (34)
Increased Antiretroviral Potency by the Addition of Enfuvirtide to a Four-Drug Regimen in Antiretroviral-Naive, HIV-Infected Patients (2006) (34)
The changing face of HIV/AIDS in treated patients. (2009) (34)
Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study). (2010) (34)
Peak Bone Mass in Young HIV-Infected Patients Compared With Healthy Controls (2014) (34)
HIV protease inhibitors and dyslipidemia. (2003) (34)
Hospital outbreak of scabies stemming from two AIDS patients with Norwegian scabies (1990) (34)
Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure. (2010) (34)
The potential role of interleukin-2 in patients with HIV infection. (2002) (33)
SAMHD1 Specifically Affects the Antiviral Potency of Thymidine Analog HIV Reverse Transcriptase Inhibitors (2014) (33)
HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses (2015) (33)
Complete nucleotide sequence of genotype 4 hepatitis C viruses isolated from patients co-infected with human immunodeficiency virus type 1. (2007) (33)
Lack of emergence of genotypic resistance to stavudine after 2 years of monotherapy. (1997) (33)
The G1/S Specific Cyclin D2 Is a Regulator of HIV-1 Restriction in Non-proliferating Cells (2016) (33)
Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide. (2003) (33)
The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy (2006) (33)
Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues (2015) (33)
Differences in Virological Response to Pegylated Interferon and Ribavirin between Hepatitis C Virus (Hcv)-Monoinfected and HCV–Hiv-Coinfected Patients (2008) (32)
Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching (2008) (32)
RNA editing by ADAR1 regulates innate and antiviral immune functions in primary macrophages (2017) (32)
Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy. (2013) (32)
Asymptomatic esophageal candidiasis in the acquired-immunodeficiency-syndrome-related complex. (1986) (32)
Epistasis among deleterious mutations in the HIV-1 protease. (2009) (32)
Parotid lipomatosis in HIV positive patients: a new clinical disorder associated with protease inhibitors (1998) (32)
Reduced Fitness of HIV-1 Resistant to Cxcr4 Antagonists (2003) (32)
A Bacteriophage Lambda-Based Genetic Screen for Characterization of the Activity and Phenotype of the Human Immunodeficiency Virus Type 1 Protease (2000) (31)
[Resistance to protease inhibitors]. (2001) (31)
Changes in Viral Load in People with Virological Failure who Remain on the Same Haart Regimen (2002) (31)
Post-Exposure Prophylaxis for HIV Infection: A Clinical Trial Comparing Lopinavir/Ritonavir versus Atazanavir Each with Zidovudine/Lamivudine (2012) (31)
HIV endocytosis after dendritic cell to T cell viral transfer leads to productive virus infection. (2009) (31)
Anti-HIV activity of a novel aminoglycoside-arginine conjugate. (2002) (31)
Anti-human immunodeficiency virus activity of novel aminoglycoside-arginine conjugates at early stages of infection. (2000) (31)
Relapsing systemic infection due to Rhodococcus equi in a drug abuser seropositive for human immunodeficiency virus. (1991) (31)
Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment‐naïve, HIV‐1‐infected patients at 48 weeks (2013) (31)
Results of a Study of Prolonging Treatment with Pegylated Interferon-α2A plus Ribavirin in HIV/HCV-Coinfected Patients with No Early Virological Response (2005) (31)
The infectious synapse formed between mature dendritic cells and CD4+ T cells is independent of the presence of the HIV-1 envelope glycoprotein (2013) (31)
Plasma and Intracellular (Peripheral Blood Mononuclear Cells) Pharmacokinetics of Once-Daily Raltegravir (800 Milligrams) in HIV-Infected Patients (2010) (31)
Antiretroviral Treatment Simplification With 3 NRTIs or 2 NRTIs Plus Nevirapine in HIV-1-Infected Patients Treated With Successful First-Line HAART (2005) (30)
Human immunodeficiency virus type 1 population bottleneck during indinavir therapy causes a genetic drift in the env quasispecies. (2000) (30)
Four-year safety with polyacrylamide hydrogel to correct antiretroviral-related facial lipoatrophy. (2009) (30)
Pulse Wave Velocity as Index of Arterial Stiffness in HIV-Infected Patients Compared With a Healthy Population (2014) (30)
Inhibition of herpes simplex virus type 1 by the CDK6 inhibitor PD-0332991 (palbociclib) through the control of SAMHD1. (2016) (30)
Variability in the Plasma Concentration of Efavirenz and Nevirapine is Associated with Genotypic Resistance after Treatment Interruption (2008) (30)
Monitoring Natural SARS-CoV-2 Infection in Lions (Panthera leo) at the Barcelona Zoo: Viral Dynamics and Host Responses (2021) (30)
Strategies for overcoming resistance in HIV-1 infected patients receiving HAART. (2004) (30)
Once-daily dosing of nevirapine in HAART. (2007) (30)
Highly active antiretroviral therapy and incidence of cervical squamous intraepithelial lesions among HIV-infected women with normal cytology and CD4 counts above 350 cells/mm3. (2007) (30)
COVIDApp as an Innovative Strategy for the Management and Follow-Up of COVID-19 Cases in Long-Term Care Facilities in Catalonia: Implementation Study (2020) (30)
A Brief and Feasible Paper-Based Method to Screen for Neurocognitive Impairment in HIV-Infected Patients: The NEU Screen (2013) (30)
Validation of estimated renal function measurements compared with the isotopic glomerular filtration rate in an HIV-infected cohort. (2010) (30)
Herb-Drug Interaction between Echinacea purpurea and Etravirine in HIV-Infected Patients (2012) (30)
Lack of Longitudinal Intrapatient Correlation between p24 Antigenemia and Levels of Human Immunodeficiency Virus (HIV) Type 1 RNA in Patients with Chronic HIV Infection during Structured Treatment Interruptions (2004) (29)
Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study. (2000) (29)
Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice. (2007) (29)
Lack of evidence for protease evolution in HIV-1-infected patients after 2 years of successful highly active antiretroviral therapy. (2004) (29)
High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response. (1999) (29)
Twice-weekly dapsone-pyrimethamine for preventing PCP and cerebral toxoplasmosis. (1991) (29)
Increased expression of SAMHD1 in a subset of HIV-1 elite controllers. (2014) (29)
Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial. (2013) (29)
Virological Efficacy in Cerebrospinal Fluid and Neurocognitive Status in Patients with Long-Term Monotherapy Based on Lopinavir/Ritonavir: An Exploratory Study (2013) (29)
The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI * (2011) (29)
Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals. (2011) (29)
Unexpected synergistic HIV neutralization by a triple microbicide produced in rice endosperm (2018) (28)
Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels. (2015) (28)
Inhibition of Coreceptor-Independent Cell-to-Cell Human Immunodeficiency Virus Type 1 Transmission by a CD4-Immunoglobulin G2 Fusion Protein (2005) (28)
Incidence and clinical significance of anti-ENA antibodies in systemic lupus erythematosus. Estimation by counterimmunoelectrophoresis. (1984) (28)
Longitudinal study on mitochondrial effects of didanosine-tenofovir combination. (2006) (28)
Increased ex vivo cell death of central memory CD4 T cells in treated HIV infected individuals with unsatisfactory immune recovery (2015) (28)
Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment. (2006) (28)
Effect of Milk Thistle on the Pharmacokinetics of Darunavir-Ritonavir in HIV-Infected Patients (2012) (28)
Chemokine and chemokine receptor expression after combined anti-HIV-1 interleukin-2 therapy. (1999) (28)
HIV-1 capture and antigen presentation by dendritic cells: enhanced viral capture does not correlate with better T-Cell activation (2012) (28)
3′-Azido-2′,3′-Dideoxythymidine (Zidovudine) Uptake Mechanisms in T Lymphocytes (2005) (28)
2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies. (2012) (28)
Characterization of the Influence of Mediator Complex in HIV-1 Transcription* (2014) (28)
Anti-HIV-1 Activity of Enfuvirtide (T-20) by Inhibition of Bystander Cell Death (2002) (27)
Inhibition of HIV‐1 replication by RNA interference of p53 expression (2006) (27)
Epidemiological Data of Different Human Papillomavirus Genotypes in Cervical Specimens of HIV-1-Infected Women Without History of Cervical Pathology (2009) (27)
Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects. (2004) (27)
LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy. (2012) (27)
Relative Fitness and Replication Capacity of a Multinucleoside Analogue-Resistant Clinical Human Immunodeficiency Virus Type 1 Isolate with a Deletion of Codon 69 in the Reverse Transcriptase Coding Region (2007) (27)
Viral Evolution during Structured Treatment Interruptions in Chronically Human Immunodeficiency Virus-Infected Individuals (2002) (27)
Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target (2017) (27)
Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster (2021) (26)
Darunavir Inhibitory Quotient Predicts the 48-Week Virological Response to Darunavir-Based Salvage Therapy in Human Immunodeficiency Virus-Infected Protease Inhibitor-Experienced Patients (2008) (26)
Prevalence of HIV Protease Mutations on Failure of Nelfinavir-Containing HAART: A Retrospective Analysis of Four Clinical Studies and Two Observational Cohorts (2002) (26)
Inhibition of human immunodeficiency virus type 1 infection in macrophages by an alpha-v integrin blocking antibody. (2006) (26)
Gene editing using a zinc-finger nuclease mimicking the CCR5Δ32 mutation induces resistance to CCR5-using HIV-1. (2014) (26)
Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach. (2008) (26)
Concomitant Use of an Active Boosted Protease Inhibitor with Enfuvirtide in Treatment-Experienced, HIV-Infected Individuals: Recent Data and Consensus Recommendations (2006) (26)
Prevalence and Route of Transmission of Infection With a Novel DNA Virus (TTV), Hepatitis C Virus, and Hepatitis G Virus in Patients Infected With HIV (2000) (25)
Canine Hepacivirus NS3 Serine Protease Can Cleave the Human Adaptor Proteins MAVS and TRIF (2012) (25)
HIV type 1 fitness evolution in antiretroviral-experienced patients with sustained CD4+ T cell counts but persistent virologic failure. (2005) (25)
Human papillomavirus HPV-16, 18, 52 and 58 integration in cervical cells of HIV-1-infected women. (2010) (25)
Antiretroviral Simplification with Darunavir/Ritonavir Monotherapy in Routine Clinical Practice: Safety, Effectiveness, and Impact on Lipid Profile (2012) (25)
Viral dynamics in patients with monkeypox infection: a prospective cohort study in Spain (2022) (25)
Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA/Plan Nacional sobre el Sida en 2013 para el tratamiento antirretroviral inicial en adultos infectados por el virus de la inmunodeficiencia humana (2012) (25)
Dynamics of CD8 T-Cell Activation After Discontinuation of HIV Treatment Intensification (2013) (25)
Compensatory mutations rescue the virus replicative capacity of VIRIP-resistant HIV-1. (2011) (25)
Asymptomatic leishmaniasis in the acquired immunodeficiency syndrome (AIDS) (1989) (25)
Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients (2012) (25)
Oral human papillomavirus type-specific infection in HIV-infected men: a prospective cohort study among men who have sex with men and heterosexual men. (2014) (24)
Psychological impact of structured treatment interruptions in patients with prolonged undetectable HIV-1 viral loads. (2001) (24)
Raltegravir Susceptibility and Fitness Progression of HIV Type-1 Integrase in Patients on Long-Term Antiretroviral Therapy (2008) (24)
Pneumocystis jirovecii pneumonia in HIV-1-infected patients in the late-HAART era in developed countries (2013) (24)
Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response (2013) (24)
Classification Models for Neurocognitive Impairment in HIV Infection Based on Demographic and Clinical Variables (2014) (24)
Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial. (2014) (24)
Lack of evidence of a stable viral load set‐point in early stage asymptomatic patients with chronic HIV‐1 infection (1998) (24)
CD4(+) and CD8(+) T cell death during human immunodeficiency virus infection in vitro. (2001) (24)
Modelled in vivo HIV Fitness under drug Selective Pressure and Estimated Genetic Barrier Towards Resistance are Predictive for Virological Response (2008) (24)
Approach to amoebic colitis: Epidemiological, clinical and diagnostic considerations in a non-endemic context (Barcelona, 2007-2017) (2019) (24)
HTLV-I in Spain (1990) (23)
Changes in survival over time after a first episode of Pneumocystis carinii pneumonia for european patients with acquired immunodeficiency syndrome (1995) (23)
Minimal Removal of Raltegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease (2010) (23)
Pigs are not susceptible to SARS‐CoV‐2 infection but are a model for viral immunogenicity studies (2020) (23)
Methylation regulation of Antiviral host factors, Interferon Stimulated Genes (ISGs) and T-cell responses associated with natural HIV control (2020) (23)
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. (2016) (23)
Review of atazanavir: a novel HIV protease inhibitor (2005) (23)
Genetic Screen for Monitoring Hepatitis C Virus NS3 Serine Protease Activity (2003) (23)
Chronological brain lesions after SARS-CoV-2 infection in hACE2-transgenic mice (2021) (23)
Routine screening of anal cytology in HIV-infected subjects and the impact on invasive anal cancer. A prospective cohort study. (2020) (23)
Screening for SARS-CoV-2 Antigen Before a Live Indoor Music Concert: An Observational Study (2021) (23)
ADAR1 affects HCV infection by modulating innate immune response (2018) (23)
[Recommendations of GESIDA (Grupo de Estudio de SIDA)/National Plan on AIDS with respect to the anti-retroviral treatment in adult patients infected with the human immunodeficiency virus in the year 2000 (II)]. (2000) (22)
Simplification Therapy with Once-Daily Didanosine, Tenofovir and Efavirenz in HIV-1-Infected Adults with Viral Suppression Receiving a More Complex Antiretroviral Regimen: Final Results of the EFADITE Trial (2005) (22)
ADS-J1 Inhibits HIV-1 Entry by Interacting with gp120 and Does Not Block Fusion-Active gp41 Core Formation (2010) (22)
A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy. (2011) (22)
Different selection patterns of resistance and cross-resistance to HIV-1 agents targeting CCR5. (2010) (22)
Primary HIV‐1 drug resistance in Spain before and after the introduction of protease inhibitors (2001) (22)
Lopinavir/Ritonavir Pharmacokinetics in HIV and Hepatitis C Virus Co-Infected Patients without Liver Function Impairment (2007) (22)
Inappropriate sinus tachycardia in post-COVID-19 syndrome (2022) (22)
Prevalence and route of transmission of infection with a novel DNA virus (TTV), hepatitis C virus, and hepatitis G virus in patients infected with HIV. (2000) (22)
[Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project]. (2005) (22)
Progression of liver fibrosis in HIV/hepatitis C virus‐coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline (2014) (22)
Hyaluronic acid, transforming growth factor‐β1 and hepatic fibrosis in patients with chronic hepatitis C virus and human immunodeficiency virus co‐infection (2009) (22)
Interleukin-7-Dependent Production of RANTES That Correlates with Human Immunodeficiency Virus Disease Progression (2003) (22)
Liver Toxicity of Initial Antiretroviral Drug Regimens Including Two Nucleoside Analogs Plus One Non-Nucleoside Analog or One Ritonavir-Boosted Protease Inhibitor in HIV/HCV-Coinfected Patients (2012) (22)
Long-term effectiveness and safety outcomes in HIV-1-infected patients after a median time of 6 years on nevirapine. (2009) (22)
Simplification of Antiretroviral Treatment from Darunavir/Ritonavir Monotherapy to Darunavir/Cobicistat Monotherapy: Effectiveness and Safety in Routine Clinical Practice. (2019) (22)
Liver biopsy in fever of unknown origin. (1980) (22)
A distinctive cytologic pattern for diagnosing tuberculous lymphadenitis in AIDS. (1993) (21)
Epidemiological, clinical, diagnostic and economic features of an immigrant population of chronic schistosomiasis sufferers with long-term residence in a non-endemic country (North Metropolitan area of Barcelona, 2002-2016) (2017) (21)
Evaluation of the putative role of C‐C chemokines as protective factors of HIV‐1 infection in seronegative hemophiliacs exposed to contaminated hemoderivatives (2000) (21)
Differential prevalence of the HLA-C -- 35 CC genotype among viremic long term non-progressor and elite controller HIV+ individuals. (2012) (21)
The DAD Study Group. Combination antiretroviral therapy and the risk of myocardial infarction (2003) (21)
Different Plasma Markers of Inflammation Are Influenced by Immune Recovery and cART Composition or Intensification in Treated HIV Infected Individuals (2014) (21)
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study (2018) (21)
The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors (2007) (21)
High prevalence of signs of renal damage despite normal renal function in a cohort of HIV-infected patients: evaluation of associated factors. (2014) (21)
Consensus statement of the European guidelines on clinical management of HIV-1 tropism testing (2010) (21)
Cutaneous vasculitis associated with propylthiouracil therapy. (1987) (20)
Stromal-cell-derived factor 1 prevents the emergence of the syncytium-inducing phenotype of HIV-1 in vivo. (2001) (20)
Phenotypic Hypersusceptibility to Multiple Protease Inhibitors and Low Replicative Capacity in Patients Who Are Chronically Infected with Human Immunodeficiency Virus Type 1 (2005) (20)
Efficacy of adding indinavir to previous reverse transcriptase nucleoside analogues in relation to genotypic and phenotypic resistance development in advanced HIV-1-infected patients. (1998) (20)
A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals. (2008) (20)
Antiretroviral treatment switch strategies for lowering the costs of antiretroviral therapy in subjects with suppressed HIV-1 viremia in Spain (2013) (20)
β5 Integrin Is the Major Contributor to the αv Integrin-Mediated Blockade of HIV-1 Replication (2011) (20)
Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy. (2005) (20)
HIV-1 resistance to the anti-HIV activity of a shRNA targeting a dual-coding region. (2008) (20)
Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC (1996) (20)
Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP) (2011) (20)
Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals (2014) (20)
Stable neutralizing antibody levels six months after mild and severe COVID-19 episode (2020) (20)
Time of Progression to Osteopenia/Osteoporosis in Chronically HIV-Infected Patients: Screening DXA Scan (2012) (20)
SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells (2021) (20)
Efavirenz: resistance and cross-resistance. (1999) (19)
New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors. (2014) (19)
Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. (2017) (19)
Catalytic efficiency and phenotype of HIV-1 proteases encoding single critical resistance substitutions. (2002) (19)
Highly pathogenic adapted HIV-1 strains limit host immunity and dictate rapid disease progression (2014) (19)
Lung cancer in HIV-infected patients in the combination antiretroviral treatment era. (2015) (19)
Differential expression of the cytokine receptors for human interleukin (IL)‐12 and IL‐18 on lymphocytes of both CD45RA+ and CD45RO+ phenotype from tonsils, cord and adult peripheral blood (2004) (19)
Comparison of two different strategies of treatment with zoledronate in HIV‐infected patients with low bone mineral density: single dose versus two doses in 2 years (2015) (19)
Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group. (1998) (19)
Evaluation of the Innate Immune Modulator Acitretin as a Strategy To Clear the HIV Reservoir (2017) (19)
Silent HIV infection in heterosexual partners of seropositive drug abusers in Spain (1990) (19)
[Disseminated histoplasmosis and AIDS. Report of 4 cases]. (1996) (19)
Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19 (2022) (19)
Piglets inoculated by different routes are not susceptible to SARS-CoV-2, but those inoculated parenterally were immunized against the virus. (2020) (18)
No detection of the NS5B S282T mutation in treatment-naïve genotype 1 HCV/HIV-1 coinfected patients using deep sequencing. (2013) (18)
Presence of Genotypic Resistance in Nucleoside Analogue-Treated HIV-1-Infected Patients with Undetectable Viral Load (1999) (18)
Alternative effector-function profiling identifies broad HIV-specific T-cell responses in highly HIV-exposed individuals who remain uninfected. (2015) (18)
Enhancement of Antiviral CD8+ T-Cell Responses and Complete Remission of Metastatic Melanoma in an HIV-1-Infected Subject Treated with Pembrolizumab (2019) (18)
Decreasing prevalence of HCV coinfection in all risk groups for HIV infection between 2004 and 2011 in Spain (2015) (18)
RNA interference as a tool for exploring HIV-1 robustness. (2011) (18)
From TMC114 to darunavir: five years of data on efficacy. (2013) (18)
Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV‐1‐infected subjects with dyslipidaemia (2017) (18)
Complexity and Catalytic Efficiency of Hepatitis C Virus (HCV) NS3 and NS4A Protease Quasispecies Influence Responsiveness to Treatment with Pegylated Interferon plus Ribavirin in HCV/HIV-Coinfected Patients (2011) (18)
Clinical and Emotional Factors Related to Erectile Dysfunction in HIV-Infected Men (2016) (18)
Novel Monocyclam Derivatives as HIV Entry Inhibitors: Design, Synthesis, Anti‐HIV Evaluation, and Their Interaction with the CXCR4 Co‐receptor (2010) (18)
Genetic Screen for Monitoring Severe Acute Respiratory Syndrome Coronavirus 3C-Like Protease (2004) (18)
Resistance of the human immunodeficiency virus to the inhibitory action of negatively charged albumins on virus binding to CD4. (1999) (18)
COVIDApp: A Health Application as an Innovative Strategy for the Management and Follow-Up of the COVID-19 Pandemic in Long-Term Care Facilities in Catalonia. (2020) (18)
Virological Failure among Patients on Haart from across Europe: Results from the Eurosida Study (1999) (18)
Purifying selection of CCR5-tropic human immunodeficiency virus type 1 variants in AIDS subjects that have developed syncytium-inducing, CXCR4-tropic viruses. (2006) (17)
Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapy. (2000) (17)
Efficacy of the somatostatin analogue (SMS-201-995), Sandostatin, for cryptosporidial diarrhoea in patients with AIDS. (1989) (17)
Evaluation of the anti-HIV activity of natalizumab, an antibody against integrin alpha4 (2009) (17)
In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial (2020) (17)
Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning? (2010) (17)
Discovery of Novel Non‐Cyclam Polynitrogenated CXCR4 Coreceptor Inhibitors (2008) (17)
New molecular method for the detection of human papillomavirus type 16 integration. (2010) (17)
Trans-infection but Not Infection from within Endosomal Compartments after Cell-to-cell HIV-1 Transfer to CD4+ T Cells* (2012) (17)
Human Papillomavirus 16 Integration and Risk Factors Associated in Anal Samples of HIV-1 Infected Men (2010) (17)
Randomised Study to Assess the Efficacy and Safety of Once-Daily Etravirine-Based Regimen as a Switching Strategy in HIV-Infected Patients Receiving a Protease Inhibitor–Containing Regimen. Etraswitch Study (2014) (17)
Cumulative risk for developing hyperlipidemia in HIV-infected patients treated with protease inhibitors (1999) (16)
Effect of lithium on HIV-1 expression and proviral reservoir size in the CD4+ T cells of antiretroviral therapy suppressed patients (2014) (16)
Liver stiffness regression after successful Hepatitis C treatment is independent of HIV coinfection (2019) (16)
Leishmaniasis in HIV-infected persons: a review. (1997) (16)
Use of a physiologically based pharmacokinetic model to simulate drug–drug interactions between antineoplastic and antiretroviral drugs (2016) (16)
HIV exposed seronegative individuals show antibodies specifically recognizing native HIV envelope glycoprotein (2013) (16)
Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors (2011) (16)
Elevated humoral response to cytomegalovirus in HIV-infected individuals with poor CD4+ T-cell immune recovery (2017) (16)
Lack of concordance between residual viremia and viral variants driving de novo infection of CD4+ T cells on ART (2016) (16)
Monotherapy with boosted PIs as an ART simplification strategy in clinical practice. (2014) (16)
Preferential attachment of HIV particles to activated and CD45RO+CD4+ T cells. (2002) (16)
Changes in T-cell subsets in HIV–HCV-coinfected patients during pegylated interferon-α2a plus ribavirin treatment (2010) (16)
A Double-Blind , Placebo-Controlled Trial of Maraviroc in Treatment-Experienced Patients Infected with Non-R 5 HIV-1 (2009) (16)
Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients. (2007) (16)
Hyaluronic Acid Levels Predict Increased Risk of Non-Aids Death in Hepatitis-Coinfected Persons Interrupting Antiretroviral Therapy in the Smart Study (2011) (16)
Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals (2021) (16)
Diverse combinatorial design, synthesis and in vitro evaluation of new HEPT analogues as potential non-nucleoside HIV-1 reverse transcription inhibitors. (2012) (16)
Combined assessment of peritumoral Th1/Th2 polarization and peripheral immunity as a new biomarker in the prediction of BCG response in patients with high-risk NMIBC (2019) (15)
In–Depth Characterization of Viral Isolates from Plasma and Cells Compared with Plasma Circulating Quasispecies in Early HIV-1 Infection (2012) (15)
Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects. (2004) (15)
Optimal timing for initiation of highly active antiretroviral therapy in treatment-naïve human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS Cohort. (2013) (15)
Evolution of cervical cytologic changes among HIV-infected women with normal cytology in the HAART era. (2007) (15)
Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to Protease Inhibitors (2017) (15)
The reconstitution of the thymus in immunosuppressed individuals restores CD4‐specific cellular and humoral immune responses (2011) (15)
Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral-experienced patients. (2004) (15)
Heterogeneous Infectivity and Pathogenesis of SARS-CoV-2 Variants Beta, Delta and Omicron in Transgenic K18-hACE2 and Wildtype Mice (2022) (15)
SAMHD1 is active in cycling cells permissive to HIV‐1 infection (2017) (15)
Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1–Infected Patients Starting Efavirenz, Lopinavir–Ritonavir, or Atazanavir–Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial) (2015) (15)
Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy. (2011) (15)
Antigen Production After Latency Reversal and Expression of Inhibitory Receptors in CD8+ T Cells Limit the Killing of HIV-1 Reactivated Cells (2019) (15)
Evolution of HIV drug Resistance in Zidovudine/Zalcitabine- and Zidovudine/ Didanosine-Experienced Patients Receiving Lamivudine-Containing Combination Therapy (1998) (15)
Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment-naïve, HIV-1-infected patients (2010) (15)
Zinc Finger Endonuclease Targeting PSIP1 Inhibits HIV-1 Integration (2014) (15)
[Abdominal tuberculosis in patients with acquired immunodeficiency syndrome]. (1991) (15)
Single oral dose of maraviroc does not prevent ex-vivo HIV infection of rectal mucosa in HIV-1 negative human volunteers (2015) (15)
Antibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies (2018) (15)
Viremic HIV Infected Individuals with High CD4 T Cells and Functional Envelope Proteins Show Anti-gp41 Antibodies with Unique Specificity and Function (2012) (15)
Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients (2022) (15)
Efficacy and Safety of Switching from Enfuvirtide to Raltegravir in Patients with Virological Suppression (2009) (14)
Early detection of HIV infection and of asymptomatic sexually transmitted infections among men who have sex with men. (2017) (14)
Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV‐1‐infected patients with multidrug‐resistant virus: a multicentre pilot study (2008) (14)
Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials. (2010) (14)
Goiter as a manifestation of disseminated aspergillosis in a patient with AIDS. (1993) (14)
A Cost-Benefit Analysis of the COVID-19 Asymptomatic Mass Testing Strategy in the North Metropolitan Area of Barcelona (2021) (14)
HIV-1 Tropism Testing in Subjects Achieving Undetectable HIV-1 RNA: Diagnostic Accuracy, Viral Evolution and Compartmentalization (2013) (14)
A Cost–Benefit Analysis of COVID-19 Vaccination in Catalonia (2021) (14)
Long-term HIV-1 infection induces an antiviral state in primary macrophages. (2016) (14)
Assessing main death pathways in T lymphocytes from HIV infected individuals (2013) (14)
Naive CD4(+) T cells and recent thymic emigrant levels in treated individuals with HIV: clinical relevance. (2006) (14)
CCR5 inhibitors: promising yet challenging. (2007) (14)
Removal of Dolutegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease (2016) (14)
Phase II study of durvalumab (MEDI4736) in cancer patients HIV-1-infected. (2019) (14)
Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences. (2015) (14)
Human Papillomavirus Genotype Distribution and Human Papillomavirus 16 and Human Papillomavirus 18 Genomic Integration in Invasive and In Situ Cervical Carcinoma in Human Immunodeficiency Virus-Infected Women (2011) (14)
P-glycoprotein (ABCB1) activity decreases raltegravir disposition in primary CD4+P-gphigh cells and correlates with HIV-1 viral load (2016) (14)
Pharmacokinetics of Fosamprenavir plus Ritonavir in Human Immunodeficiency Virus Type 1-Infected Adult Subjects with Hepatic Impairment (2009) (14)
Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients. (2007) (13)
Effect of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Polymorphism Leu-214 on Replication Capacity and Drug Susceptibility (2009) (13)
Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs (2018) (13)
Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA para el tratamiento antirretroviral inicial (2012) (13)
HIV-1 envelope glycoproteins isolated from Viremic Non-Progressor individuals are fully functional and cytopathic (2019) (13)
Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif (2017) (13)
Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients. (1998) (13)
Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir (2001) (13)
Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study (2013) (13)
Recomendaciones sobre tratamiento antirretroviral (1998) (13)
Endoribonuclease-Prepared Short Interfering RNAs Induce Effective and Specific Inhibition of Human Immunodeficiency Virus Type 1 Replication (2007) (13)
Extremely low viral reservoir in treated chronically HIV-1-infected individuals (2020) (13)
Association between HIV replication and cholesterol in peripheral blood mononuclear cells in HIV-infected patients interrupting HAART. (2007) (13)
Induction of interleukins IL‐6 and IL‐8 by siRNA (2006) (13)
The Aging Imageomics Study: rationale, design and baseline characteristics of the study population (2020) (13)
Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Immunoglobulin Demonstrates Potent Neutralization and Antibody-Dependent Cellular Cytotoxicity and Phagocytosis Through N and S Proteins (2021) (13)
Short-term anti-HIV activity of the combination of didanosine and hydroxyurea. (1996) (13)
Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up. (1999) (13)
Evaluation of the Anti-HIV Activity of Natalizumab—An Antibody Against Integrin alpha4 (2009) (12)
Multiparametric Assay To Screen and Dissect the Mode of Action of Anti-Human Immunodeficiency Virus Envelope Drugs (2005) (12)
Synthesis, Biological Activity, and ADME Properties of Novel S‐DABOs/N‐DABOs as HIV Reverse Transcriptase Inhibitors (2012) (12)
Prevalence of CCR5-tropic HIV-1 Among Treatment-Experienced Individuals in Spain (2009) (12)
Pan-resistant HIV-1 emergence in the era of integrase strand-transfer inhibitors: a case report. (2020) (12)
Low levels of adherence to antiretroviral therapy in HIV-1-infected women with menstrual disorders. (2009) (12)
A Specific Mobile Health Application for Older HIV-Infected Patients: Usability and Patient's Satisfaction. (2020) (12)
Alternation of Antiretroviral Drug Regimens for HIV Infection. Efficacy, Safety and Tolerability at Week 96 of the Swatch Study (2004) (12)
Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014). (2014) (12)
Consumo de plantas medicinales en los pacientes infectados por el virus de la inmunodeficiencia humana. Patrones de uso y factores relacionados (2012) (12)
Hepatitis C virus NS3/4A quasispecies diversity in acute hepatitis C infection in HIV‐1 co‐infected patients (2014) (12)
Therapeutic management of bone demineralization in the HIV-infected population (2007) (12)
Circumcision and penile human papillomavirus prevalence in human immunodeficiency virus-infected men: heterosexual and men who have sex with men. (2013) (12)
Emotional impact of premature aging symptoms in long-term treated HIV-infected subjects. (2012) (12)
Nonhuman TRIM5 Variants Enhance Recognition of HIV-1-Infected Cells by CD8+ T Cells (2016) (12)
Unboosted Atazanavir Plus Co-formulated Lamivudine/Abacavir as a Ritonavir-Sparing Simplification Strategy in Routine Clinical Practice (2009) (12)
Safety and efficacy of an induction dose of pegylated interferon alpha‐2a on early hepatitis C virus kinetics in HIV/HCV co‐infected patients: the CORAL‐1 multicentre pilot study (2007) (12)
Search for SARS-CoV-2 inhibitors in currently approved drugs to tackle COVID-19 pandemia (2020) (12)
Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals (2014) (12)
AIDS and Kaposi sarcoma pre-1979 (1990) (12)
Cellular HIV-1 DNA Levels in Drug Sensitive Strains Are Equivalent to Those in Drug Resistant Strains in Newly-Diagnosed Patients in Europe (2010) (11)
[Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012]. (2012) (11)
Design, synthesis and biological evaluation of pyrido[2,3-d]pyrimidin-7-(8H)-ones as HCV inhibitors. (2016) (11)
Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals (2016) (11)
Variability in non-nucleoside reverse transcriptase and protease inhibitor concentrations among HIV-infected adults in routine clinical practice. (2006) (11)
Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients. (2000) (11)
Analysis of neurocognitive function and CNS endpoints in the PROTEA trial: darunavir/ritonavir with or without nucleoside analogues (2014) (11)
Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48‐week data from a randomized, double‐blind trial (2001) (11)
Performance of SARS-CoV-2 Antigen-Detecting Rapid Diagnostic Tests for Omicron and Other Variants of Concern (2022) (11)
The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype (2012) (11)
Ten-Year Safety with Polyacrylamide Gel Used to Correct Facial Lipoatrophy in HIV-Infected Patients. (2015) (11)
Efficacy of etravirine combined with darunavir or other ritonavir‐boosted protease inhibitors in HIV‐1‐infected patients: an observational study using pooled European cohort data (2015) (11)
Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection (2022) (11)
Prevalence, evolution, and related risk factors of kidney disease among Spanish HIV-infected individuals (2017) (11)
Could CD4 Capture by CD8+ T Cells Play a Role in HIV Spreading? (2010) (11)
A Cohort Study of the Food Effect on Virological Failure and Treatment Discontinuation in Patients on HAART Containing Didanosine Enteric-Coated Capsules (FOODDIe Study) (2006) (11)
Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients (2018) (11)
Efficiency of Drug Resistance Genotypic Tests in Specimens with Low HIV Viral Load (1998) (10)
[Use of herbal remedies among HIV-infected patients: patterns and correlates]. (2012) (10)
Natural History of Anal Squamous Intraepithelial Lesions in HIV-Positive Men with Normal Baseline Cytology. (2019) (10)
Association between two mass-gathering outdoor events and incidence of SARS-CoV-2 infections during the fifth wave of COVID-19 in north-east Spain: A population-based control-matched analysis (2022) (10)
Hydroxychloroquine pre-exposure prophylaxis for COVID-19 in healthcare workers (2020) (10)
Routine Screening of Anal Cytology in Persons With Human Immunodeficiency Virus and the Impact on Invasive Anal Cancer: A Prospective Cohort Study (2019) (10)
Beta5 integrin is the major contributor to the alphaV integrin-mediated blockade of HIV-1 replication (2011) (10)
Baseline Resistance and Virological Outcome in Patients with Virological Failure who Start a Regimen Containing Abacavir: Eurosida Study (2004) (10)
Absence of genetic diversity reduction in the HIV-1 integrated proviral LTR sequence population during successful combination therapy. (2001) (10)
Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015). (2015) (10)
Rare LEDGF/p75 genetic variants in white long-term nonprogressor HIV+ individuals. (2012) (10)
Complications of the acquired immunodeficiency syndrome. (1986) (10)
Evaluation of the Cytopathicity (Fusion/Hemifusion) of Patient-Derived HIV-1 Envelope Glycoproteins Comparing Two Effector Cell Lines (2012) (10)
Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM) (2021) (10)
Secondary diabetes induced by megestrol acetate therapy in a patient with AIDS-associated cachexia. (1993) (10)
Effectiveness of physically ablative and pharmacological treatments for anal condyloma in HIV-infected men (2018) (10)
Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression. (2015) (10)
Antiretroviral therapy suppressed participants with low CD4+ T-cell counts segregate according to opposite immunological phenotypes (2016) (10)
Recurrent coronary disease in HIV‐infected patients: role of drug–drug interactions (2018) (10)
Comparison of the f-HPV typing™ and Hybrid Capture II® assays for detection of high-risk HPV genotypes in cervical samples. (2012) (10)
Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients. (2011) (10)
Computational Studies Identifying Entry Inhibitor Scaffolds Targeting the Phe 43 Cavity of HIV‐1 gp120 (2013) (9)
Effect of liver fibrosis on long-term mortality in HIV/hepatitis C virus-coinfected individuals who are evaluated to receive interferon therapies in the highly active antiretroviral therapy era. (2012) (9)
Analysis of chemokine and cytokine expression in patients with HIV and GB virus type C coinfection. (2005) (9)
Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease (2015) (9)
Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999 (2008) (9)
Transient Treatment Exclusively Containing Nucleoside Analogue Reverse Transcriptase Inhibitors in Highly Antiretroviral-Experienced Patients Preserves Viral Benefit When a Fully Active Therapy Was Initiated (2008) (9)
Memory B cell dysregulation in HIV-1-infected individuals (2017) (9)
Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis. (2012) (9)
Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis (2022) (9)
Ex vivo production of autologous whole inactivated HIV-1 for clinical use in therapeutic vaccines. (2011) (9)
Implications of HIV Drug Resistance on First- and Second-Line Therapies in Resource-Limited Settings: Report from a Workshop Organized by the Collaborative HIV and Anti-HIV Drug Resistance Network (2013) (9)
First Detection of SARS-CoV-2 Delta (B.1.617.2) Variant of Concern in a Dog with Clinical Signs in Spain (2021) (9)
Association between First-Year Virological Response to Raltegravir and Long-Term Outcomes in Treatment-Experienced Patients with HIV-1 Infection (2015) (9)
Cerebral toxoplasmosis and prophylaxis for Pneumocystis carinii pneumonia. (1992) (9)
Partial Immunological and Mitochondrial Recovery after Reducing Didanosine doses in Patients on Didanosine and Tenofovir-Based Regimens (2008) (9)
Review: immunologic response to protease inhibitor-based highly active antiretroviral therapy: a review. (2007) (9)
Spontaneous resolution of Candida esophagitis in a seroconverting patient for HIV antibodies. (1988) (9)
Self-collected mid-nasal swabs and saliva specimens, compared with nasopharyngeal swabs, for SARS-CoV-2 detection in mild COVID-19 patients (2021) (9)
Ritonavir boosting dose reduction from 100 to 50 mg does not change the atazanavir steady-state exposure in healthy volunteers. (2012) (9)
Siglec-1 on dendritic cells mediates SARS-CoV-2 trans-infection of target cells while on macrophages triggers proinflammatory responses (2021) (9)
Noncyclam tetraamines inhibit CXC chemokine receptor type 4 and target glioma-initiating cells. (2012) (9)
Learning from drug changes in antiretroviral therapy. (2013) (9)
Effectiveness of Efavirenz Compared with Ritonavir-Boosted Protease-Inhibitor-Based Regimens as Initial Therapy for Patients with Plasma HIV-1 RNA above 100,000 Copies/Ml (2014) (9)
The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults (2016) (9)
HLA class I protective alleles in an HIV-1-infected subject homozygous for CCR5-Δ32/Δ32. (2013) (9)
Association between polymorphisms in genes involved in lipid metabolism and immunological status in chronically HIV-infected patients. (2015) (9)
The Genome-wide Methylation Profile of CD4+ T Cells From Individuals With Human Immunodeficiency Virus (HIV) Identifies Distinct Patterns Associated With Disease Progression (2020) (9)
Initiation, changes in use and effectiveness of highly active anti-retroviral therapy in a cohort of injecting drug users (2002) (9)
The use of corticosteroids in the control of the adverse effects of cotrimoxazole in AIDS patients suffering from PCP. (1991) (9)
Quejas cognitivas en personas con infeccion por el virus de la inmunodeficiencia humana en Espana: prevalencia y variables relacionadas (2014) (9)
A non-infectious cell-based phenotypic assay for the assessment of HIV-1 susceptibility to protease inhibitors. (2012) (8)
Pharmacological Modulation of SAMHD1 Activity by CDK4/6 Inhibitors Improves Anticancer Therapy (2020) (8)
Plasmapheresis in Felty's syndrome. (1985) (8)
Role of viral kinetics under HCV therapy in HIV/HCV-coinfected patients. (2005) (8)
Combined Antiretroviral Therapy and Immune Pressure Lead to In Vivo HIV-1 Recombination With Ancestral Viral Genomes (2011) (8)
Cetylpyridinium Chloride Mouthwash to Reduce Shedding of Infectious SARS-CoV-2: A Double-Blind Randomized Clinical Trial (2022) (8)
New antiretroviral drugs and approaches to HIV treatment (2003) (8)
Limited humoral and specific T-cell responses after SARS-CoV-2 vaccination in PLWH with poor immune reconstitution (2022) (8)
Treatment simplification to once daily darunavir/ ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients (2010) (8)
Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antiretroviral therapy-naive and -experienced patients. (2014) (8)
Lack of short-term efficacy of N-acetyl-L-cysteine in human immunodeficiency virus-positive patients with CD4 cell counts < 250/mm3. (1995) (8)
Novel Two-Round Phenotypic Assay for Protease Inhibitor Susceptibility Testing of Recombinant and Primary HIV-1 Isolates (2012) (8)
Preserved immune functionality and high CMV-specific T-cell responses in HIV-infected individuals with poor CD4+ T-cell immune recovery (2017) (8)
Immunological function restoration with lopinavir/ritonavir versus efavirenz containing regimens in HIV-infected patients: a randomized clinical trial. (2014) (8)
Saquinavir/ritonavir monotherapy as a new nucleoside-sparing maintenance strategy in long-term virologically suppressed HIV-infected patients. (2010) (8)
Outcome of hospitalized patients with COVID-19 pneumonia treated with high-dose immunoglobulin therapy in a prospective case series (2020) (8)
High-dose intravenous immunoglobulins might modulate inflammation in COVID-19 patients (2021) (8)
Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia (2015) (8)
Critical Presentation of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection: A Case Report (2021) (8)
Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalization. (2021) (8)
Interruptions of Antiretroviral Therapy in HIV Infection : Are they Detrimental to Neurocognitive Functioning ? (2015) (8)
Short-Term Effect of Ritonavir-Boosted Atazanavir in Hepatitis B and/or C Co-infected, Treatment-Experienced HIV Patients (2009) (8)
Valor de la carga viral del VIH-1 y de los linfocitos CD4+ como determinantes de la progresión a sida y de la supervivencia (1998) (7)
A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study. (2008) (7)
Evolution of the human immunodeficiency virus type 1 protease: effects on viral replication capacity and protease robustness. (2012) (7)
El papel de las combinaciones de antirretrovirales a dosis fijas en el tratamiento de la infección por VIH-1 (2010) (7)
A randomized, open-label study of a nucleoside analogue reverse transcriptase inhibitor-sparing regimen in antiretroviral-naive HIV-infected patients. (2009) (7)
Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption (2019) (7)
Cetylpyridinium chloride-containing mouthwashes reduce in vitro SARS-CoV-2 infectivity (2020) (7)
Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study (2017) (7)
Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial (2018) (7)
Biomarker candidates for progression and clinical management of COVID-19 associated pneumonia at time of admission (2022) (7)
Clinical course impacts early kinetics and long-term magnitude and amplitude of SARS-CoV-2 neutralizing antibodies beyond one year after infection (2021) (7)
Effects of integrase inhibitor-based antiretroviral therapy on brain outcomes according to time since acquisition of HIV-1 infection (2021) (7)
Effect of Nevirapine on the Steady-State Trough Concentrations of Atazanavir in HIV-Infected Patients Receiving Atazanavir/Ritonavir (2010) (7)
Variable endothelial cell function restoration after initiation of two antiretroviral regimens in HIV-infected individuals (2017) (7)
Gut microbiome signatures linked to HIV-1 reservoir size and viremia control (2021) (7)
Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens (2017) (7)
Evolution of Genotypic Resistance to Nucleoside Analogues in Patients Receiving Protease Inhibitor-Containing Regimens (1998) (7)
Therapeutic challenge for Isospora belli enteritis in an AIDS patient who developed Lyell syndrome after co-trimoxazole therapy. (1989) (7)
Long-term survivors of human immunodeficiency virus type 1 infection. (1995) (7)
Convalescent plasma for outpatients with early COVID-19 (2021) (7)
Brief Report: Impaired CD4 T-Cell Response to Autophagy in Treated HIV-1–Infected Individuals (2017) (7)
Long-term changes in bone mineral density after switching to a protease inhibitor monotherapy in HIV-infected subject. (2015) (6)
Contribución de la captura de híbridos de segunda generación del virus del papiloma humano en el cribado de afección cervical en mujeres con infección por el virus de la inmunodeficiencia humana (2005) (6)
Mpox in people with advanced HIV infection: a global case series (2023) (6)
Highly functional Cellular Immunity in SARS-CoV-2 Non-Seroconvertors is associated with immune protection (2021) (6)
Stable HIV-1 integrase diversity during initial HIV-1 RNA Decay suggests complete blockade of plasma HIV-1 replication by effective raltegravir-containing salvage therapy (2013) (6)
Safety of non-nucleoside reverse transcriptase therapy: data from the EuroSIDA study (2003) (6)
Candida esophagitis in patients infected by human immune deficiency virus: treatment and prognostic significance. (1988) (6)
Potential prescribing issues among older HIV‐infected subjects in a Mediterranean cohort: Does the current prevalence give cause for concern? (2020) (6)
Therapeutic drug monitoring of antiretroviral agents scenario. (2004) (6)
A step ahead on the HIV collaboratory. (2009) (6)
Prescribing and using self-injectable antiretrovirals: How concordant are physician and patient perspectives? (2009) (6)
Saquinavir exposure in HIV-infected patients with chronic viral hepatitis. (2009) (6)
Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029. (2015) (6)
Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens. (2012) (6)
Dual effect of the broad spectrum kinase inhibitor midostaurin in acute and latent HIV-1 infection. (2019) (6)
[Recommendation of GESIDA (AIDS Study Group)/National Plan on AIDS with respect to the anti-retroviral treatment in adult patients infected with the human immunodeficiency virus in the year 2000 (I)]. (2000) (6)
Short-term risk for AIDS-indicator diseases predicted by plasma HIV-1 RNA and CD4+ lymphocytes. (1999) (6)
Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC (2014) (6)
Symposium - Leishmaniasis in HIV Infection (2003) (6)
RECall for Automated Genotypic Tropism Testing (2013) (6)
Prospective Study to Assess Progression of Renal Markers after Interruption of Tenofovir due to Nephrotoxicity (2016) (6)
2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings (2018) (5)
SARS-CoV-2 Infection Modulates ACE2 Function and Subsequent Inflammatory Responses in Swabs and Plasma of COVID-19 Patients (2021) (5)
2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings (2018) (5)
HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy (2020) (5)
Incidence and clinical management of oral human papillomavirus infection in men: a series of key short messages (2014) (5)
Impact of protease inhibitors on the evolution of urinary markers (2016) (5)
Distribution of CD31 on CD4 T-Cells from Cord Blood, Peripheral Blood and Tonsil at Different Stages of Differentiation (2010) (5)
Impact of fixed-dose combinations of antiretrovirals on prevalence trends of HIV resistance: a 7 year follow-up study. (2015) (5)
TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals (2008) (5)
Drug-resistance mutations number and K70R or T215Y/F substitutions predict treatment resumption during guided treatment interruptions. (2008) (5)
Oesophageal candidiasis in people with primary HIV infection. (1991) (5)
Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial (2022) (5)
High risk and probability of progression to osteoporosis at 10 years in HIV-infected individuals: the role of PIs (2018) (5)
Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtide (2006) (5)
Polymorphisms in LPL, CETP, and HL protect HIV-infected patients from atherogenic dyslipidemia in an allele-dose-dependent manner (2014) (5)
ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study (2014) (5)
Cost-effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components. (2018) (5)
Dissemination of Mycobacterium tuberculosis is associated to a SIGLEC1 null variant that limits antigen exchange via trafficking extracellular vesicles (2021) (5)
Lymphogranuloma venerium proctitis in the setting of HIV: a case report and differential diagnosis. (2009) (5)
Asymptomatic HIV (1988) (5)
Atlas of the HIV-1 Reservoir in Peripheral CD4 T Cells of Individuals on Successful Antiretroviral Therapy (2021) (5)
Polymorphisms in LPL, CETP, and HL protect HIV-infected patients from atherogenic dyslipidemia in an allele-dose-dependent manner. (2015) (5)
SARS-CoV-2 infection suppresses ACE2 function and antiviral immune response in the upper respiratory tract of infected patients (2020) (5)
Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection. (2016) (5)
Control of HIV-1 Pathogenesis in Viremic Nonprogressors Is Independent of Gag-Specific Cytotoxic T Lymphocyte Responses (2018) (5)
[Role of fixed-dose combinations of antiretrovirals in HIV-1 therapy]. (2010) (5)
[Evidence of HTLV-1 infection in different groups at risk in Barcelona]. (1990) (5)
Liver sinusoidal dilatation in familial Mediterranean fever. (1986) (4)
Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review (2021) (4)
Prevalence of Ischemic Heart Disease and Management of Coronary Risk in Daily Clinical Practice: Results from a Mediterranean Cohort of HIV-Infected Patients (2014) (4)
Evaluation of Protease Inhibitors Containing Tubes for MS‐Based Plasma Peptide Profiling Studies (2014) (4)
Utility of echocardiography in AIDS. (1990) (4)
Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals (2022) (4)
Safety and effi cacy of the peptide-based therapeutic vaccine for HIV-1 , Vacc-4 x : a phase 2 randomised , double-blind , placebo-controlled trial (2014) (4)
Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group. (1996) (4)
Functional Analyses Reveal Extensive RRE Plasticity in Primary HIV-1 Sequences Selected under Selective Pressure (2014) (4)
The Magnitude of Interferon-γ Responses to Human Cytomegalovirus Is Predictive for HIV-1 Disease Progression (2008) (4)
Hydroxychloroquine Alone or in Combination with Cobicistat-Boosted Darunavir for Treatment of Mild COVID-19: A Cluster-Randomized Clinical Trial (2020) (4)
Liver-related death among HIV/HCV coinfected indivi duals, implications for the era of directly acting ant ivirals (2014) (4)
Efficacy and safety of switching enfuvirtide to raltegravir in patients with viral suppression (2008) (4)
Mitochondrial Effects of a 24-Week Course of Pegylated-Interferon plus Ribavirin in Asymptomatic HCV/HIV Co-Infected Patients on Long-Term Treatment with Didanosine, Stavudine or Both (2004) (4)
Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa (2016) (4)
Clinical approach to drug resistance interpretation: expert advice (2007) (4)
Role of Siglecs in viral infections: A double-edged sword interaction (2022) (4)
Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial (2022) (4)
Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial. (2021) (4)
[Granulomatous hepatitis. Etiologic study of 107 cases (author's transl)]. (1979) (4)
Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2 (2021) (4)
[Recommendations of the Spanish AIDS Study Group (GESIDA) and the National Aids Plan (PNS) for antiretroviral treatment in adult patients with human immunodeficiency virus infection in 2002]. (2002) (4)
Kinetics of humoral immune response over 17 months of COVID-19 pandemic in a large cohort of healthcare workers in Spain: the ProHEpiC-19 study (2022) (4)
Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals (2022) (4)
Management of bone mineral density in HIV-infected patients (2016) (4)
Impact of Mass Workplace COVID-19 Rapid Testing on Health and Healthcare Resource Savings (2021) (4)
[Analysis of costs and cost-effectiveness of preferred GESIDA/National AIDS Plan regimens for initial antiretroviral therapy in human immunodeficiency virus infected adult patients in 2013]. (2012) (4)
Evidence for Preferential Genotyping of a Minority Human Immunodeficiency Virus Population Due to Primer-Template Mismatching during PCR-Based Amplification (2005) (4)
[Asymptomatic visceral leishmaniasis in a patient with acquired immunodeficiency syndrome]. (1990) (4)
Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1 (2018) (4)
Significant changes in integrase-associated HIV-1 replication capacity between early and late isolates. (2013) (4)
Similarly high prevalence of hypovitaminosis D in HIV-infected subjects with and without low bone mineral density (2012) (4)
A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV (2020) (4)
Gp120/CD4 Blocking Antibodies Are Frequently Elicited in ART-Naïve Chronically HIV-1 Infected Individuals (2015) (4)
Withdrawing inactive NRTIs in HIV-1 subjects with suppressed viraemia: a randomized trial. (2016) (4)
Short Communication: Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical Trial. (2016) (4)
Antibody kinetics to SARS-CoV-2 at 13.5 months, by disease severity (2021) (4)
Virological response with fully active etravirine (ETR; TMC125) after 48 weeks of treatment: pooled results from the DUET-1 and DUET-2 trials (2008) (3)
Association between resistance and CD4-count change in patients on ART with ongoing viraemia (2007) (3)
Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19 (2023) (3)
Comparison of the efficacy of HAART: single, dual or triple-class antiretroviral therapy (2004) (3)
Costs to Achieve Undetectable HIV RNA with Darunavir-Containing Highly Active Antiretroviral Therapy in Highly Pretreated Patients (2012) (3)
The role of inactive nucleoside/nucleotide reverse transcriptase inhibitors in salvage therapy for drug-resistant HIV-1 infection in the era of new classes and new generation antiretrovirals. (2011) (3)
VIP-SPOT: an Innovative Assay To Quantify the Productive HIV-1 Reservoir in the Monitoring of Cure Strategies (2021) (3)
[Cognitive complaints in people with human immunodeficiency virus in Spain: prevalence and related variables]. (2014) (3)
Hidden costs of antiretroviral treatment: the public health efficiency of drug packaging (2015) (3)
Plasma HIV-1 tropism and risk of short-term clinical progression to AIDS or death (2014) (3)
Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine. (1996) (3)
NEU Screen Shows High Accuracy in Detecting Cognitive Impairment in Older Persons Living With HIV (2019) (3)
Genotypic and phenotypic evolution of HIV type-1 protease during in vitro sequential or concomitant combination of atazanavir and amprenavir (2010) (3)
The multiple nucleoside analogue resistance mutations confer cross-resistance to abacavir (1999) (3)
SARS-CoV-2 B.1.351 (beta) variant shows enhanced infectivity in K18-hACE2 transgenic mice and expanded tropism to wildtype mice compared to B.1 variant (2021) (3)
Compromised immunologic recovery in patients receiving tipranavir/ritonavir coadministered with tenofovir and didanosine in Randomized Evaluation of Strategic Intervention in multidrug-resiStant patients with tipranavir (RESIST) studies. (2007) (3)
Susceptibility of Human Lymphoid Tissue Cultured ex vivo to Xenotropic Murine Leukemia Virus-Related Virus (XMRV) Infection (2012) (3)
Aggressive human papillomavirus (HPV)-11-related sinonasal inverted papilloma in an HIV-infected patient and the quadrivalent HPV vaccine: a case report. (2015) (3)
Plasma HIV-1 Tropism and the Risk of Short-Term Clinical Progression to AIDS or Death (2014) (3)
The rate of accumulation of NNRTI resistance in patients kept on a virologically failing regimen containing NNRTI: a EuroSIDA study (2008) (3)
Applications of 3-aminolactams: design, synthesis, and biological evaluation of a library of potential dimerisation inhibitors of HIV1-protease. (2012) (3)
1208TiPA phase II exploratory study of durvalumab (MEDI4736) in HIV-1 patients with advanced solid tumors (2017) (3)
Optimal Use of Transient Elastography and Acoustic Radiation Force Impulse to Stage Liver Fibrosis in HIV/HCV‐Coinfected Patients in Clinical Practice (2018) (3)
[GESIDA Consensus document on the use of resistance studies in clinical practice]. (2001) (3)
Efficacy and safety of ritonavir dose reduction based on the tipranavir inhibitory quotient in HIV-infected patients on salvage antiretroviral therapy with tipranavir/ritonavir. (2010) (3)
Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study (2022) (3)
Safety and tolerability of etravirine (ETR; TMC125) in hepatitis B and/or C co-infected patients in DUET-1 and DUET-2: pooled 48-week results (2008) (3)
Increased peripheral proinflammatory cytokines in HIV-1-infected patients with prolonged viral suppression suffering from high psychological stress. (2009) (3)
Unusual myelopathy in an HIV-infected patient with spastic paraparesis. (1991) (3)
Modulation of DNA Damage Response by SAM and HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase (SAMHD1) Determines Prognosis and Treatment Efficacy in Different Solid Tumor Types (2022) (3)
Single nucleotide polymorphisms in PNPLA3, ADAR-1 and IFIH1 are associated with advanced liver fibrosis in patients co-infected with HIV-1//hepatitis C virus (2021) (3)
Incidence of squamous intraepithelial lesions in the anal canal of HIV‐infected men with normal cytology, up to 8 years of follow‐up (2016) (3)
The clinical challenges of lifetime HAART (2008) (3)
Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients. (2016) (3)
Alleles at rs4273729 in the chromosome 6 do not predict response to peg-interferon-α and ribavirin therapy in hepatitis C virus/HIV-1-coinfected patients. (2012) (3)
Evaluating the accuracy of self-collected swabs for the diagnosis of monkeypox (2022) (3)
Rate of accumulation of thymidine analogue mutations (TAM) in patients left on virologically failing regimens containing zidovudine (ZDV) or stavudine (d4T) (2007) (3)
Pre-clinical search of SARS-CoV-2 inhibitors and their combinations in approved drugs to tackle COVID-19 pandemic (2020) (3)
Predictors of Having a Resistance Test following Confirmed Virological Failure of Combination Antiretroviral Therapy: Data from Eurosida (2011) (3)
Effect of An Induction Period of Pegylated Interferon-α2A and Ribavirin on Early Virological Response in HIV–HCV-Coinfected Patients: Results from the Coral-2 Study (2011) (3)
Lamivudine, a reverse transcriptase inhibitor, rescues cognitive deficits in a mouse model of down syndrome (2022) (3)
Etravirine in protease inhibitor‐free antiretroviral combination therapies (2012) (3)
Multifocal splenic abscesses in AIDS-related tuberculosis. (1992) (3)
Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities (2022) (3)
Second European Round Table on the Future Management of HIV (2015) (3)
Mild improvement in mitochondrial function after a 3-year antiretroviral treatment interruption despite persistent impairment of mitochondrial DNA content. (2010) (3)
Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio (2015) (3)
MULTILOBATED NUCLEI IN PERIPHERAL BLOOD LYMPHOCYTES FROM HIV+ PATIENTS (1989) (3)
Safety and Immunogenicity of a Recombinant Protein RBD Fusion Heterodimer Vaccine against SARS-CoV-2: preliminary results of a phase 1-2a dose-escalating, randomized, double-blind clinical trial. (2022) (3)
Duración de las combinaciones de fármacos antirretrovirales (2004) (3)
Interacciones medicamentosas de darunavir (2008) (3)
Etravirina: barrera genética y desarrollo de resistencias (2009) (3)
Anti-SARS-CoV-2 hyperimmune immunoglobulin provides potent and robust neutralization capacity and antibody-dependent cellular cytotoxicity and phagocytosis induction through N and S proteins (2021) (2)
Remote Health Monitoring in the Workplace for Early Detection of COVID-19 Cases during the COVID-19 Pandemic Using a Mobile Health Application: COVIDApp. (2021) (2)
Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions (2013) (2)
Evolution of the gut microbiome following acute HIV-1 infection (2019) (2)
Glucocorticoids’ treatment impairs the medium-term immunogenic response to SARS-CoV-2 mRNA vaccines in Systemic Lupus Erythematosus patients (2022) (2)
[Pharmacological interactions with darunavir]. (2008) (2)
International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK (2016) (2)
Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in hamsters (2021) (2)
Cloxacillin-lnduced Leukopenia (1985) (2)
Pulmonary function tests in AIDS. (1989) (2)
Pharmacokinetic/pharmacodynamic analysis of romidepsin used as an HIV latency reversing agent. (2020) (2)
[HIV sexual transmission. Should we review the risk among individuals with long-term viral supression?]. (2010) (2)
Clinical results of infrared coagulation as a treatment of high-grade anal dysplasia: a systematic review (2019) (2)
Association between lipid genetic and immunological status in chronically HIV-infected patients (2014) (2)
Adherence and health beliefs in a psychoeducative intervention in naïve HIV-1-infected men: the PROADH study (2012) (2)
Launching a multidisciplinary European collaboration towards a cure for HIV: The EU2Cure Consortium (2021) (2)
Real World Patient-reported Outcomes in HIV-infected Adults Switching to EVIPLERA®, Because of a Previous Intolerance to cART. PRO-STR Study (2018) (2)
Long-term changes in bone mineral density after switching to a protease inhibitor monotherapy in HIV-infected subjects (2015) (2)
International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK (2016) (2)
Perfil de resistencias y barrera genética de dolutegravir (2015) (2)
Cetylpyridinium chloride-containing mouthwashes reduce the infectivity of SARS-CoV-2 variants in vitro (2020) (2)
Fatal Fast-Evolution of Nasopharyngeal Squamous Cell Carcinoma in an HIV Patient with EBV and HPV (-16 AND -33) in Blood Serum (2008) (2)
[Value of HIV-1 viral load and CD4 lymphocyte count as determinants of progression to AIDS and survival]. (1998) (2)
[Recommendations on antiretroviral treatment. The AIDS Study Group of the Spanish Society of Infectious Diseases and Clinical Microbiology]. (1998) (2)
[Barriers to ART initiation in HIV infected subjects and with treatment indication in Spain. Why don't they start their treatment? Bridgap Study]. (2015) (2)
Quality of T-cell responses versus reduction in viral load: results from an exploratory phase II clinical study of Vacc-4x, a therapeutic HIV vaccine (2012) (2)
HIV and aging, biological mechanisms, and therapies: What do we know? (2022) (2)
Study to determine the improvement in neuropsychiatric symptoms after changing the responsible antiretroviral drug to nevirapine: the RELAX study (2012) (2)
Corrigendum to ‘Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study)’ EClinicalMedicine 11 (2019) 65–80 (2020) (2)
[Contribution of human papillomavirus second-generation hybrid capture test for the diagnosis of cervical pathology in HIV-infected outpatients]. (2005) (2)
Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome (2022) (2)
Baseline Factors associated with Haematological Toxicity that Leads to a Dosage Reduction of Pegylated Interferon-α2a and Ribavirin in HIV- and HCV-Coinfected Patients on HCV Antiviral Therapy (2005) (2)
HIV Coreceptor Switch Induced by Antagonism to CCR5 (2007) (2)
TL1A–DR3 Plasma Levels Are Predictive of HIV-1 Disease Control, and DR3 Costimulation Boosts HIV-1–Specific T Cell Responses (2020) (2)
[Mutations resulting in resistence of antiretroviral drugs in HIV-infected patients]. (2005) (2)
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Infection and Humoral Responses Against Different Variants of Concern in Domestic Pet Animals and Stray Cats from North‐Eastern Spain (2022) (2)
Comparison of regimens as initial therapy for HIV. (2004) (2)
Acute encephalopathy during combined phenothiazine and lithium treatment. A new case with low blood lithium (1980) (2)
DRV concentrations and viral load in CSF in patients on DRV/r 600/100 or 800/100mg once daily plus two NRTI (2014) (2)
Mutaciones de resistencia a agentes antirretrovirales en pacientes con infección por el virus de la inmunodeficiencia humana (2005) (2)
Lumbosciatic syndrome caused by aneurysm of the abdominal aorta (1989) (2)
Incidence of cervical high-grade squamous intraepithelial lesions in HIV-1-infected women with no history of cervical pathology: up to 17 years of follow-up (2018) (2)
Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines Panel. (2003) (2)
507 Early prediction of sustained virological response (SVR) during treatment with peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (RBV) (COPEGUS®) in patients with HCV/HIV co-infection: Results from the aids pegasys ribavirin international co-infectio (abstract withdrawn) (2004) (2)
Management of HIV/hepatitis C virus-coinfected patient non-responders to hepatitis C virus antiviral therapy and relapsers (2007) (2)
Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease. (2020) (2)
Trial of Three Rounds of Mass Azithromycin Administration for Yaws Eradication. (2022) (2)
[Dilated cardiomyopathy in the acquired immunodeficiency syndrome]. (1989) (2)
Prevalence of HPV-DNA and E6 mRNA in lung cancer of HIV-infected patients (2022) (2)
Analysis of genotypic and phenotypic clinical cut‐off levels for ritonavir‐boosted saquinavir (2006) (2)
DNA-MVA Prime-Boost Vaccine Eliciting T-Cell Specificities Associated with HIV-1 Control Is Highly Immunogenic in Mice and Breaks CTL Immunodominance (2013) (2)
Schistosomiasis Among Female Migrants in Non-endemic Countries: Neglected Among the Neglected? A Pilot Study (2022) (2)
[Heterosexual transmission of the human immunodeficiency virus in stable sexual partners of drug addicts]. (1987) (1)
HIV conserved region vaccine in early cART-treated subjects (BCN01): impact on immunogenicity and the latent reservoir (2015) (1)
Visual inspection with acetic acid ( ViA ) and lugols iodine ( ViLi ) is a feasible screening tool for cervical cancer in rural india (1)
Association between visceral abdominal fat accumulation and severity of liver fibrosis in nondiabetic individuals coinfected by HIV and HCV. (2020) (1)
SARS-CoV-2 Cellular Infection and Therapeutic Opportunities: Lessons Learned from Ebola Virus (2021) (1)
Limited immune responses after three months of BNT162b2 vaccine in SARS-CoV-2 uninfected elders living in long-term care facilities (2021) (1)
tonsils, cord and adult peripheral blood (2004) (1)
Posicionamiento de darunavir en la terapia antirretroviral (2008) (1)
[External technic of amplification and wave filter: its usefulness in cardiological diagnosis]. (1979) (1)
HPTN 069/ACTG A5305: phase II study of maraviroc-containing regimens for HIV PrEP in US women; Postive impact of a randomized controlled trial of the Uthando Lwethu ("Our Love") intervention on rates of couples HIV testing in rural South Africa (2016) (1)
Quality of T-cell responses versus reduction in viral load: results from an exploratory phase II clinical study of Vacc-4x, a therapeutic HIV vaccine (2012) (1)
Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort (2018) (1)
HIV-1 R5+ /X4- tropic viruses can be inhibited in vitro as well as in vivo by maraviroc: a refined analysis of patients enrolled in the Phase IIb study A4001029 (2011) (1)
Preserved central nervous system functioning after use of romidepsin as a latency-reversing agent in an HIV cure strategy (2021) (1)
Predictive value of early virological reduction (EVR) in the response at 24 weeks (W) of HCV treatment with Peg-interferon (Peg-IFN) & ribavirine (RBV) in HIV-infected patients (P) (2003) (1)
[Primary hepatic lymphoma in acquired immunodeficiency syndrome]. (1989) (1)
Adherencia al tratamiento del HIV, resistencia a las medicinas antirretrovirales y a la evaluación de la atención sanitaria (2002) (1)
Comprar Guía Práctica Del Sida. Clínica, Diagnóstico Y Tratamiento 2017 14ª Ed. | J. Gatell | 9788488825223 | Antares (2016) (1)
Monoterapia con lopinavir potenciado con ritonavir como estrategia de simplificación del tratamiento antirretroviral en la práctica clínica (2008) (1)
Genetic evolution of GB virus C/hepatitis G virus (GBV-C/HGV) under interferon pressure. (2000) (1)
Susceptibility of Domestic Goat (Capra aegagrus hircus) to Experimental Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) B.1.351/Beta Variant (2022) (1)
401 Increased rantes steady state MRNA levels in liver biopsies of HIV/HCV coinfected patients (2004) (1)
Recomendaciones sobre tratamiento antirretroviral en 1998 (1998) (1)
Chronic HCV Infection in HIV-Positive Patients: A New Challenge (2003) (1)
ALTA PREVALENCIA DEL VIRUS DEL PAPILOMA HUMANO EN UNA POBLACIÓN ESPAÑOLA CON NEOPLASIA DE ESÓFAGO (2009) (1)
Transmisión sexual del virus de la inmunodeficiencia humana. ¿Debe replantearse el riesgo en individuos con supresión virológica muy prolongada? (2010) (1)
Serious Fatal and Non-Fatal Non-AIDS D efining Illnesses (non-ADI) in Europe (2009) (1)
[Etravirine: genetic barrier and resistance development]. (2009) (1)
Cell adhesion through aV-containing integrins is required for efficient HIV-1 infection in macrophages. Commentary (2009) (1)
SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity (2021) (1)
Usability of a Mobile Health Application (“app”) in Older HIV-Infected Patients: An Emerging Tool for Care, Education, and Prevention: Randomized Controlled Trial (Preprint) (2019) (1)
Comparison between mid-nasal swabs and buccal swabs for SARS-CoV-2 detection in mild COVID-19 patients (2022) (1)
Interpretation of resistance data from randomized trials of first-line antiretroviral treatment. (2012) (1)
HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics (2013) (1)
Hyaluronic Acid as a Prognostic Marker of Hepatic Encephalopathy and Liver-related Death in HIV/Viral Hepatitis Coinfected Patients (2009) (1)
CD32 expression is associated to T-cell activation and is not a marker of the HIV-1 reservoir (2018) (1)
La era del tratamiento antirretroviral de gran actividad... y de la coinfección por el virus de la hepatitis C (2004) (1)
[Resistance genotyping in patients with therapeutic failure]. (2006) (1)
[Heterosexual transmission of HTLV-III/LAV]. (1986) (1)
[Acquired immune deficiency syndrome and related conditions]. (1986) (1)
Accentuated aging associated with HIV in a Mediterranean setting occurs mainly in persons aged>70 years: a comparative cohort study (Over50 cohort) (2021) (1)
Limited cross-border infections in patients newly diagnosed with HIV in Europe (2013) (1)
[Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy]. (2011) (1)
Skewed Cellular Distribution and Low Activation of Functional T-Cell Responses in SARS-CoV-2 Non-Seroconvertors (2022) (1)
Attachment Styles, Condomless Sex, and Drugs in HIV-Positive Gay and Bisexual Men (2020) (1)
Prescribing issues among older HIV-infected persons in a Mediterranean cohort: Does the current prevalence give cause for concern? (2020) (1)
Predicting Virological Response to HIV Treatment Over Time: A Tool for Settings With Different Definitions of Virological Response (2019) (1)
Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice (2010) (1)
[England's index in microcytosis]. (1985) (1)
A surprising evolution from oral human papillomavirus 16 infection to lymph node metastasis of tonsilar squamous cell carcinoma in an HIV-infected patient. (2012) (1)
[Acute pancreatitis in patients infected with the human immunodeficiency virus]. (1995) (1)
Small form factor flow virometer for SARS-CoV-2. (2022) (1)
SARS-CoV-2 transmission in an indoor mass-gathering live music event. A randomized clinical trial. (2021) (1)
[Lopinavir/ritonavir monotherapy as a simplification strategy in antiretroviral therapy in clinical practice]. (2008) (1)
The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype (2012) (1)
UpdateoftheDrugResistanceMutationsinHIV-1: Spring 2008 (2008) (1)
[Ceroid granuloma of the gallbladder]. (1984) (1)
Purifying selection of CCR 5-tropic human immunodeficiency virus type 1 variants in AIDS subjects that have developed syncytium-inducing , CXCR 4-tropic viruses (2006) (1)
The EuResist expert model for customised HAART optimisation: 2010 update and extension to newest compounds (2010) (1)
Neurologic and psychiatric safety profile of TMC278 compared with efavirenz in treatment-naïve, HIV-1-infected patients: pooled analysis from the randomized, double-blind, Phase III ECHO and THRIVE trials at 48 weeks (2011) (1)
Our experience with negative images of bacilli in Fine‐Needle Aspiration Biopsies (FNAB) from lymph nodes of patients with Acquired Immunodeficiency Syndrome (AIDS) (1994) (1)
[Bronchogenic carcinoma in patients with human immunodeficiency virus infection]. (1996) (1)
Altered T‐cell subset distribution in the viral reservoir in HIV‐1‐infected individuals with extremely low proviral DNA (LoViReTs) (2022) (1)
Aging‐associated symptoms in the physician‐patient dialogue in a group of long‐term diagnosed HIV‐infected individuals (2012) (1)
Immunological and virological activity of zalcitabine and zidovudine in combination in HIV-positive people with CD4 cell counts of between 200-500 cells/mm3. (1997) (1)
National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults (2016) (1)
296 PEGINTERFERON ALFA-2A (40KD) PLUS 800 OR 1000/1200 MG/DAY RBV IN G1 HIV-HCV-CO-INFECTED PATIENTS: EARLY RESPONSES TO TREATMENT AND PREDICTABILITY FOR SVR IN THE PARADIGM STUDY (2010) (1)
Monotherapy with boosted protease inhibitors as antiretroviral treatment simplification strategy in the clinical setting (2012) (1)
Assessment of changes in adherence and quality of life after the simplification of antiretroviral treatment. (2003) (1)
48-week outcomes following switch from AZT/3TC to FTC/TDF (TVD) vs. continuing on AZT/3TC: 48-week interim analysis of the RECOMB trial (2008) (1)
Identifying the needs of older people living with HIV (≥ 50 years old) from multiple centres over the world: a descriptive analysis (2023) (1)
Serological Markers of Human Immunodeficiency (1988) (1)
603 Insulin resistance in co-infected HCV/HIV patients: A negative factor influencing sustained response to peginterferon plus ribavirin (2006) (1)
Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3-year results of the BICOMBO study (2010) (1)
M1973 High Prevalence of Human Papillomavirus in a Spanish Population with Esophageal Cancer (2009) (1)
IRF7 expression correlates with HIV latency reversal upon specific blockade of immune activation (2022) (1)
[Acquired immunodeficiency syndrome and cryptosporidiosis of the respiratory tract]. (1988) (1)
Helper/inducer T cells and disease progression in patients with HIV antibodies. (1987) (1)
HIV-1 trans-Infection Mediated by DCs: The Tip of the Iceberg of Cell-to-Cell Viral Transmission (2021) (1)
[Pseudopericarditis in diabetic ketoacidosis]. (1981) (1)
Cloxacillin-induced leukopenia. (1985) (1)
A simple new screening tool for diagnosing imported schistosomiasis (2022) (1)
Nitrogen positional scanning in tetramines active against HIV-1 as potential CXCR4 inhibitors. (2016) (1)
Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions (2013) (1)
[Bone tuberculosis in acquired immunodeficiency syndrome]. (1989) (1)
Immune-recovery posterior uveitis associated with inactive isolated toxoplasmic retinochoroiditis in a patient with human immunodeficiency virus. (2012) (1)
[Treatment of acute brucellosis with cotrimoxazole, doxicyclin and streptomycin. A comparative study (author's transl)]. (1980) (1)
Exposition and sequencing to antiretrovirals in HIV-1 patients with triple-class antiretroviral failure, and harbouring protease resistance mutations (2008) (0)
P03.01 High immunogenic VLP-based vaccines elicit new T cell specificities against melanoma neoantigens in mice (2021) (0)
HIV & Hepatitis in the Americas 28–30 April 2016, Mexico City, Mexico (2016) (0)
The CXCR4 Antagonist POL3026 is a Potent Inhibitor of Human Immunodeficiency Virus (2007) (0)
Monitoring SARS-CoV-2 variant transitions using differences in diagnostic cycle threshold values of target genes (2022) (0)
Modulation of the autophagic pathway inhibits HIV-1 infection in human lymphoid tissue cultured ex vivo (2022) (0)
[Yersinia enterocolitica and thalassemia: a chance association?]. (1982) (0)
Agreement and differential use of laboratory methods for the detection and quantification of SARS-CoV-2 in experimentally infected animals (2022) (0)
Effective Small Interfering RNAs Targeting AlphaV Integrin Inhibit HIV-1 Replication (2008) (0)
Anti-HIV activity of a neomycin B-arginine conjugate. (2001) (0)
A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques (2015) (0)
A Novel T-cell Vaccine Eliciting T-cell Specificities Associated with Control of HIV-1 In Humans Is Highly Immunogenic in Mice and Macaques (2014) (0)
P.411 The impact of age on sustained virological response in genotype 1 HIV-HCV co-infected patients receiving peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®): AIDS PEGASYS ribavirin co-infection trial (APRICOT) (2006) (0)
Integrin-Mediated Blockade of HIV-1 Replication (2010) (0)
Influence of the ARV regimen on the early changes in plasma HIV RNA and immune activation at initiation of antiretroviral therapy in naïve HIV-1-infected patients. (2020) (0)
Long-term satisfaction and benefits on quality of life in HIV-infected people after reparatory treatment with Aquamid®for facial Lipoatrophy (2008) (0)
Single-cell CD8+ dynamics in PLWH uncover the depletion of TIGIT+ memory HIV-1-specific cells during long-term ART (2022) (0)
Mutations in the protease gene associated with virological failure to lopinavir-containing regimens in clinical samples (2008) (0)
Author Correction to: SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells (2022) (0)
Trastuzumab resistance: Bringing tailored therapy to the clinic (2008) (0)
1275P Extended follow-up of DURVAST trial: A phase II study evaluating durvalumab treatment in HIV-1-infected patients with solid tumours by the Spanish lung cancer group (2020) (0)
Cetylpyridinium chloride-containing mouthwashes reduce the infectivity of 1 SARS-CoV-2 variants in vitro 2 3 4 (2021) (0)
Alanine-based spacers promote an efficient antigen processing and presentation in neoantigen polypeptide vaccines. (2023) (0)
[541] CONFIRMATION OF THE ACCURACY OF FIB-4, A SIMPLE MARKER OF FIBROSIS IN HCV PATIENTS WITH AND WITHOUT HIV CO-INFECTION (2007) (0)
Abstract 929: Transcriptomic analysis of pre-treatment tissue samples to predict clinical benefit to durvalumab in HIV-infected cancer patients (2020) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
[Pulmonary edema following intravenous heroin]. (1981) (0)
[T lymphocyte subpopulations, markers of the HTLV III virus and immunoglobulin levels in asymptomatic homosexuals of the Barcelona area]. (1987) (0)
[Wilson's disease: seven cases with hepatic onset (author's transl)]. (1981) (0)
[Pleural effusion as a predominant manifestation of the ovarian hyperstimulation syndrome]. (1982) (0)
COVIDApp as an Innovative Strategy for the Management and Follow-Up of COVID-19 Cases in Long-Term Care Facilities in Catalonia: Implementation Study (Preprint) (2020) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
[Peripheral gangrene following iatrogenic ergotism]. (1981) (0)
Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS‐CoV‐2 mRNA‐1237 vaccine in patients with solid tumors (2022) (0)
[Sjögren syndrome and cardiomyopathy]. (1982) (0)
[Hyperactive thyroid and parathyroid adenomas: simultaneous presentation in the same patient]. (1983) (0)
[Costal chondrosarcoma mimicking an abdominal tumor]. (1981) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
HIV‐2 in Spanish Drug Abusers (1989) (0)
ASYMPTOMATIC MONKEY POX VIRUS INFECTION: A SELF-SAMPLING SCREENING INTERVENTION ADRESSED TO GAY, BISEXUAL AND OTHER MEN WHO HAVE SEX WITH MEN AND TRANS WOMEN IN SPAIN (2023) (0)
Decrease in BIA bioelectrical parameters in women with longcovid. (2023) (0)
[Angioimmunoblastic lymphadenopathy. Immunocytochemical, morphological and mathematical study of lymph node biopsy (author's transl)]. (1981) (0)
Erratum: Castellví, M. et al. Pharmacological Modulation of SAMHD1 Activity by CDK4/6 Inhibitors Improves Anticancer Therapy. Cancers 2020, 12, 713 (2020) (0)
Impact of Obefazimod on Viral Persistence, Inflammation, and Immune Activation in People With HIV on Suppressive Antiretroviral Therapy (2022) (0)
The amino acid substitution A376S in the HIV-1 reverse transcriptase connection subdomain confers low-level phenotypic resistance to nevirapine (2010) (0)
[Resistance profile and genetic barrier of dolutegravir]. (2015) (0)
2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings. (2021) (0)
[Anti-DNA antibodies: comparison between the Crithidia luciliae technic and radioimmunoassay (Farr's technic)]. (1984) (0)
Percutaneous endoscopic feeding (PEG) of AIDS patients: An ongoing study in our unit (1997) (0)
[Risk groups in AIDS]. (1989) (0)
Biomarker candidates for progression and clinical management of COVID-19 associated pneumonia at time of admission (2022) (0)
Pneumoproteins and biomarkers of inflammation and coagulation do not predict rapid lung function decline in people living with HIV (2023) (0)
[Visceral leishmaniasis with benign course in a patient infected with human immunodeficiency virus]. (1989) (0)
Anti-SS-B antibodies in immune hemolytic anemia. (1982) (0)
Abacavir/lamivudine has shown similar efficacy to other nucleoside conventional combinations in previously HIV-infected patients: results at 48 weeks (2008) (0)
Screening NK-, B- and T-cell phenotype and function in patients suffering from Chronic Fatigue Syndrome (2013) (0)
Mutation at reverse transcriptase codon 214 is antagonist to thymidine analogue mutations (TAM) type 2 profiles and predicts virological response to thymidine analogue-containing cART regimens only if TAM type 1 profiles are concomitantly detected (2006) (0)
Barreras para el inicio del tratamiento antirretroviral en pacientes con virus de la inmunodeficiencia humana e indicación de tratamiento en España. ¿Por qué no inician tratamiento quienes lo tienen indicado? Estudio Bridgap (2015) (0)
Spectrum of liver disease in patients with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection as compared to HCV infected patients. A case-control study (2002) (0)
Diagnosis of myocarditis (1982) (0)
Anal Invasive Squamous Cell Cancer and Human Papillomavirus Distribution in HIV-Infected and Non-HIV-Infected Individuals (2014) (0)
[Angioimmunoblastic lymphadenopathy. Report of four cases (author's transl)]. (1980) (0)
Sirtuin-2, NAD-Dependent Deacetylase, Is a New Potential Therapeutic Target for HIV-1 Infection and HIV-Related Neurological Dysfunction (2023) (0)
Antithrombin III contribution to cholestasis differential diagnosis: its correlation with one stage prothrombin time and factor V. (1980) (0)
[Central nervous system disease and complement fixing anti-DNA antibodies]. (1983) (0)
Bayesian network analysis of mutational pathways to DRV resistance (2012) (0)
Comprar Guía Práctica Del Sida. Clínica, Diagnóstico Y Tratamiento 2017 14ª Ed. | D. Podzamczer | 9788488825223 | Antares (2016) (0)
Inappropriate sinus tachycardia in post-COVID-19 syndrome (2022) (0)
[Mediterranean lymphoma with secretion of lambda IgA demonstrated by analysis with immunoperoxidases]. (1985) (0)
Abdominal tuberculosis in hiv infected drug abusers (1991) (0)
HLA-C-35C/T Variant: Genetic Association to HIV-1 Disease Progression and Functional Links (2011) (0)
Low levels of anti-MPER antibodies are detectable in viremic HIV infected (2012) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
Induction strategy with enfuvirtide: results from the Fuziona study, a multicenter retrospective study in Spain (2008) (0)
Prevalence, progression, and management of advanced chronic kidney disease in a cohort of people living with HIV (2022) (0)
HIV-1 capture and antigen presentation by dendritic cells: enhanced viral capture does not correlate with better T-Cell activation (2012) (0)
Interrupciones del tratamiento en la práctica clínica (2002) (0)
Sida : saber ayuda : un programa educativo multidisciplinario para el conocimiento y la prevención del sida (1994) (0)
[Introduction. Darunavir]. (2008) (0)
Preserved immune functionality and high CMV-specific T-cell responses in HIV-infected individuals with poor CD4+ T-cell immune recovery (2017) (0)
[Evidence of infection by type 2 (HIV 2) human immunodeficiency virus in heroin addicts in Barcelona]. (1989) (0)
Vigilancia epidemiológica intensificada de arbovirosis: primer caso de dengue autóctono en Cataluña (España), zona Metropolitana Norte de Barcelona, 2018-2019 (2020) (0)
[Incidence of infection with human immunodeficiency virus and acquired immunodeficiency syndrome in a population from the Barcelona area]. (1988) (0)
SAMHD1 expression modulates innate immune activation and correlates with ovarian cancer prognosis (2023) (0)
Tratamiento antirretrovírico en los pacientes infectados por el virus de la inmunodeficiencia humana (1994) (0)
Angels in America, The Normal Heart y Positius: VIH y sida en las series de televisión (2016) (0)
Guía del manejo de las dislipemias en los pacientes infectados por el VIH: recomendaciones farmacológicas (2003) (0)
P04-13. Complex pattern of neutralization of cell-to-cell HIV transmission to activated CD4+T cells (2009) (0)
Tests de resistencia genotpica en pacientes con fracaso teraputico (2006) (0)
[Specific beta-glycoprotein of pregnancy in patients with autoimmune diseases (author's transl)]. (1982) (0)
[Salmonella enteritidis bacteremia preceding the onset of acquired immunodeficiency syndrome]. (1988) (0)
Modulation of DNA Damage Response by Samhd1 Determines Prognosis and Treatment Efficacy in Different Solid Tumor Types (2021) (0)
Safety analysis of darunavir/r (DRV/r): combined data from randomised Phase II and Phase III studies (2008) (0)
Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
A Trial of Three Rounds of Mass Drug Administration with Azithromycin for Yaws (2021) (0)
Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infection (2018) (0)
Long-term safety and efficacy of nevirapine (NVP)-based antiretroviral therapies (2008) (0)
Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
[Human immunodeficiency virus antigens and antibodies in parenteral drug addicts: correlations with a clinical study]. (1988) (0)
Maturation of Blood-Derived Dendritic Cells Enhances Human Immunodeﬁciency Virus Type 1 Capture and Transmission (cid:1) † (2007) (0)
[Overdose of zidovudine]. (1989) (0)
Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization (2023) (0)
Safety and eﬃ cacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial (2014) (0)
Antiretroviral Therapy Including Tenofovir HIV-1 Patients Treated with Combination of Reverse Transcriptase Mutation K65R in HIV-1 Subtype Is an Independent Predictor (2013) (0)
Comparison of resistance profiles between patients starting nevirapine and efavirenz in EuroSIDA (2005) (0)
Use of statistical methods in medical publications (1987) (0)
W06.167 CETP activity is not influenced by Efavirenz (2004) (0)
HIV-1 Resistance to the Anti-HIV Activity of a siRNA Targeting Rev (2007) (0)
Analysis and prediction of COVID-19 for EU-EFTA-UK and other countries Full version (2021) (0)
Serological markers of human immunodeficiency virus infection in African patients with AIDS: are they different from markers found in patients from other countries? (1988) (0)
Lopinavir-Ritonavir Abacavir , Lamivudine , or Intracellular Interactions between TDF and ( TDF ) : Investigation of Systemic and Receiving Tenofovir Disoproxil Fumarate Immunodeficiency Virus-Infected Patients Pilot Pharmacokinetic Study of Human (2009) (0)
Homology modeling of HIV-1 gp120 and docking of molecules on its surface agree with experimental data (2005) (0)
Replication Integrin-Mediated Blockade of HIV-1 v a Integrin Is the Major Contributor to the 5 b (2010) (0)
[Recommendations for antiretroviral treatment in 1998. AIDS Working Group of the Spanish Society for Infectious Diseases and Clinical Microbiology (SEIMC)]. (1998) (0)
Ultrasound-Based Assessment of Preperitoneal Fat as a Surrogate Marker of Cardiovascular Risk: Comparative Study Between People Living With HIV and Controls. (2021) (0)
Allogeneic Transplantation with CCR5 Δ32/Δ32 Cord Blood Hematopoietic Cells in a HIV-Infected Patient (2014) (0)
Dispositional optimism, perceived health competence and adherence in highly antiretroviral-experienced patients (2008) (0)
[Pharmacologic treatment of acquired immunodeficiency syndrome]. (1989) (0)
Felipe García Control of HIV-1 Replication Based Vaccine Elicits T Cell Responses Associated with − A Dendritic Cell (2012) (0)
[HTLV-1 infection in Barcelona]. (1989) (0)
Syphilis vaccine: challenges, controversies and opportunities (2023) (0)
Recomendations from GESIDA/National AIDS plan on antiretroviral therapy in adult patients infected by the human immunodeficiency virus (October 2004) (2015) (0)
ZNRD1 as a Host Cellular Factor Influencing HIV-1 Replication (2009) (0)
[Anti-DNA antibodies in systemic lupus erythematosus (author's transl)]. (1982) (0)
2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings. (2021) (0)
Incidence of Recurrent High-Grade Anal Dysplasia in HIV-1-Infected Men and Women Following Infrared Coagulation Ablation: A Retrospective Cohort Study (2021) (0)
[Difficulties in research on antibodies to HTLV-I]. (1989) (0)
Expression and functionality of anti-HIV and anticancer drug uptake transporters in immune cells (2007) (0)
Induction of IL-6 and IL-8 by siRNAs Targeting HIV Correceptor CCR5 (2007) (0)
Unraveling the antiviral activity of plitidepsin by subcellular and morphological analysis (2021) (0)
[Agenesis of the left pericardium]. (1980) (0)
Changes in codon-pair bias of human immunodeficiency virus type 1 have profound effects on virus replication in cell culture (2013) (0)
[Self-limiting hepatic and febrile manifestation of Q fever]. (1986) (0)
Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to Protease Inhibitors (2017) (0)
[ELISA method for false positive reaction for the human immunodeficiency virus in a patient with alcoholic liver disease]. (1987) (0)
Partial Immunological and Mitochondrial Recovery after Reducing Didanosine doses in Patients on Didanosine and Tenofovir-Based Regimens (2008) (0)
A case of conversion from MT-2-positive to MT-2-negative phenotype (1994) (0)
Effectiveness of first‐line antiretroviral therapy based on NNRTIs vs ritonavir‐boosted PIs in HIV‐1 infected patients with high plasma viral load (2012) (0)
Immunodiscordant responses to HAART - mechanisms and (2013) (0)
Saquinavir/ritonavir monotherapy as a new nucleoside-sparing maintenance strategy (2008) (0)
573 Early virological response (EVR) and viral kinetics during the first 12 weeks of antiviral treatment in HCV-HIV co-infected patients: Control study (2006) (0)
[Treatment of the most common infections in patients with human immunodeficiency virus infection. Task-force on AIDS of the Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica]. (1990) (0)
Stable HIV-1 integrase diversity during initial HIV-1 RNA Decay suggests complete blockade of plasma HIV-1 replication by effective raltegravir-containing salvage therapy (2013) (0)
Correlation between Clinical and Immunological Variables and Humoral Response to SARS-CoV-2 Vaccination in Adult Patients with Antibody Deficiency Disorders (2022) (0)
Natural history of HIV infection in European drug users. (1989) (0)
[Dermatomyositis associated with pulmonary fibrosis and Hashimoto's thyroiditis]. (1981) (0)
[Diagnosis of human retrovirus infections by techniques of nucleic acid amplification/hybridization]. (1990) (0)
Effect of the Human Immunodeﬁciency Virus Type 1 Reverse Transcriptase Polymorphism Leu-214 on Replication Capacity and Drug Susceptibility (cid:1) (2009) (0)
Transient therapy with quadruple NRTI provides immune stability in patients with multidrug resistant HIV-1 and no options for suppressive regimens (2008) (0)
[Detection of anti-p24 in patients with acquired immunodeficiency syndrome]. (1988) (0)
Adherence, coping strategies and depression in highly antiretroviral-experienced patients (2008) (0)
Gut microbiome signatures linked to HIV-1 reservoir size and viremia control (2022) (0)
Cost-effectiveness analysis of the daily HIV pre-exposure prophylaxis in men who have sex with men in Barcelona (2021) (0)
THU0221 Osteonecrosis and hiv infection: report of eleven cases (2001) (0)
The infectious synapse formed between mature dendritic cells and CD4+T cells is independent of the presence of the HIV-1 envelope glycoprotein (2013) (0)
Octreotide for chronic diarrhoea in AIDS. (1992) (0)
[Position of darunavir in antiretroviral therapy]. (2008) (0)
Gut microbiome signatures linked to HIV-1 reservoir size and viremia control (2022) (0)
Acceptability of HIV Vaccine - Efficacy Trials in Drug Users and Sexual Partners of HIV Infected Patients in Barcelona, Spain (2011) (0)
[Hepatic actinomycosis. A case]. (1982) (0)
Pharmacological Inhibition of IKK to Tackle Latency and Hyperinflammation in Chronic HIV-1 Infection (2022) (0)
Early diagnosis of HIV infection among men who have sex with men in Lima (Peru). A prospective cohort study. (2018) (0)
Development of Resistance to the Natural HIV-1 Entry Virus Inhibitory Peptide (VIRIP) (2010) (0)
[Intensified epidemiological surveillance of arbovirosis: First case of native dengue fever in Catalonia (Spain), Northern Metropolitan Area of Barcelona, 2018-2019]. (2021) (0)
[The era of antiretroviral therapy... and the era of hepatitis C virus coinfection]. (2004) (0)
Human papillomavirus infection and associated lesions in the cervix, anal canal, and mouth of HIV-uninfected women with different HIV risk status in Barcelona (2017) (0)
Toxic encephalopathy caused by enterobacteria. Its possible relation to hyperammonemia and hypophosphatemia (1985) (0)
[Purpura fulminans associated with varicella]. (1980) (0)
Antiretroviral resistance at virologic failure in the NEAT 001 / ANRS 143 trial : Raltegravir + 1 Darunavir / ritonavir or Tenofovir / Emtricitabine + Darunavir / ritonavir as first line 2 antiretroviral therapy 3 (2016) (0)
Erratum for Puertas et al., “VIP-SPOT: an Innovative Assay To Quantify the Productive HIV-1 Reservoir in the Monitoring of Cure Strategies” (2021) (0)
[Polymicrobial infectious endocarditis in an intravenous drug addict]. (1988) (0)
[Primary infection caused by human immunodeficiency virus: clinical and serologic aspects of 7 cases]. (1990) (0)
[Other anti-retroviral agents]. (1996) (0)
[The sexual transmission of zidovudine-resistant HIV-1 strains]. (1995) (0)
MP61-16 DETERMINATION OF IMMUNE POLARIZATION (TH1 VS TH2) IN TUMOUR TISSUE AS A PROGNOSTIC MARKER TO BCG RESPONSE IN PATIENTS WITH HIGH GRADE NON-MUSCLE INVASIVE BLADDER CÁNCER. (2016) (0)
Schistosomiasis screening in non-endemic countries from a cost perspective: Knowledge gaps and research priorities. The case of African long-term residents in a Metropolitan Area, Spain (2023) (0)
Fitness Landscape of Human Immunodeﬁciency Virus Type 1 Protease Quasispecies (cid:1) (2007) (0)
HIV-1 envelope glycoproteins isolated from Viremic Non-Progressor individuals are fully functional and cytopathic (2019) (0)
Host genetic associations with the gut microbiota in HIV-1-infected subjects: a pilot exploratory study (2018) (0)
Cross-sectional study to assess the efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies (2022) (0)
Lack of concordance between residual viremia and viral variants driving de novo infection of CD4+ T cells on ART (2016) (0)
Enhancement of antiviral CD8 T-cell responses and complete remission of metastatic melanoma in an HIV-1 infected subject treated with pembrolizumab (2019) (0)
Testingfor Automated Genotypic Tropism (2014) (0)
Back Cover: Computational Studies Identifying Entry Inhibitor Scaffolds Targeting the Phe 43 Cavity of HIV‐1 gp120 (ChemMedChem 3/2013) (2013) (0)
[Intermittent acute porphyria (author's transl)]. (1979) (0)
[Neurologic involvement in AIDS]. (1986) (0)
Restricted infection of xenotropic murine leukemia virus-related virus in human lymphoid tissue (2011) (0)
An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses (2023) (0)
[Duration of antiretroviral combinations]. (2004) (0)
[Candida albicans esophageal involvement in patients with acquired immune deficiency syndrome-related complex]. (1986) (0)
Re-examining the importance of mask-wearing at mass gathering events—Authors' reply (2022) (0)
DC-SIGN is Not Required for HIV-1 Transmission to CD4+ T Lymphocytes (2007) (0)
836 DIFFERENCES IN VIROLOGIC RESPONSE PATTERNS BETWEEN HIV/HCV CO-INFECTED AND HCV MONO-INFECTED PATIENTS TREATED WITH PEGINTERFERON AND RIBAVIRIN WITH DOSE ADJUSTED TO BODY WEIGHT (1000–1200 MG/DAY) (2008) (0)
O331 Patterns of viral suppression on cART as predictors of uncontrolled viremia after starting a new antiretroviral after 1 January 2003 (2008) (0)
HIV phenotype & genotype data highlights Lake Maggiore meeting. (1998) (0)
[Kaposi's sarcoma with primary pulmonary involvement in a parenteral drug addict with acquired immunodeficiency syndrome]. (1991) (0)
AlphaV Integrin-mediated Adhesion of Monocyte-derived Macrophages Influences HIV Infection (2008) (0)
Increased ex vivo cell death of central memory CD4 T cells in treated HIV infected individuals with unsatisfactory immune recovery (2015) (0)
SAMHD1 Is a Modulator of Nucleos(t)ide Analogues’ Efficacy (2020) (0)
Drug Resistance Mutations in HIV-1. (2002) (0)
Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients (2012) (0)
, Eva Mediator Complex in HIV-1 Transcription Characterization of the Influence of Microbiology (2014) (0)
[Consensus documents and clinical guidelines on resistance to antiretroviral agents]. (2001) (0)
Ef ﬁ cacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study (2022) (0)
Mitochondrial effects of 3 years of CD4-guided HIV treatment interruption (2008) (0)
Treatment Selective Pressure at Population Level Increases the Fitness of Wild Type HIV over Time (2010) (0)
Transcriptase Inhibitors Potency of Thymidine Analog HIV Reverse SAMHD 1 Specifically Affects the Antiviral (2014) (0)
Remodeling the bladder tumor immune microenvironment by mycobacterial species with changes in their cell envelope composition (2022) (0)
Viral and Cellular Factors Leading to the Loss of CD4 Homeostasis in HIV-1 Viremic Nonprogressors (2021) (0)
TREATMENT-ASSOCIATED POLYMORPHISMS IN PROTEASE BUT NOT IN REVERSE TRANSCRIPTASE ARE SIGNIFICANTLY ASSOCIATED WITH HIGHER VIREMIA AND LOWER CD4 CELL COUNT IN RECENTLY DIAGNOSED TREATMENT-NAIVE PATIENTS (2010) (0)
[Exacerbation of psoriasis by lithium carbonate: apropos of a case]. (1986) (0)
RNA editing by ADAR1 regulates innate and antiviral immune functions in primary macrophages (2017) (0)
[Cutaneous periarteritis nodosa associated with anti-HBcAg]. (1985) (0)
Prolonged Viral Shedding and Multiple Admissions Due to SARS-CoV-2-Associated Pneumonia in a Patient with Chronic Lymphocytic Leukemia: A Case Report (2022) (0)
Frequency of bone abnormalities and associated factors in a Spanish cohort of HIV-infected patients (2008) (0)
Comparing the prevalence of tipranavir resistance mutations in naïve, PI experienced and tipranavir experienced patients (2009) (0)
Hepatitis C Virus (HCV) Coinfection Does Not Influence the CD 4 Cell Recovery in HIV-1 Infected Patients with Maximum Virologic Suppression within the EuroSIDA Cohort (2008) (0)
Factors associated with critical care requirements in diabetic patients treated with dexamethasone for COVID-19 infection in the first wave of the pandemia (2022) (0)
Right-sided Staphylococcus aureus presenting as staphylococcal scarlet fever. (1987) (0)
Author Correction: Modulation of the autophagic pathway inhibits HIV-1 infection in human lymphoid tissue cultured ex vivo (2023) (0)
ADAR1 Function Regulates Innate Immune Activation and Susceptibility to Viral Infections (2020) (0)
[Hepatic tuberculosis]. (1981) (0)
Proof-of-principle evaluation of predictive performance for therapy outcome of baseline estimated fitness and genetic barrier towards resistance in a clinical cohort of HIV-1-treated patients (2007) (0)
Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trial (2023) (0)
Untangling Pathways to Tipranavir Resistance in Patients Infected with Various HIV-1 Subtypes (2009) (0)
HIV antigenaemia and prognosis. (1987) (0)
Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals (2014) (0)
Low levels of anti-MPER antibodies are detectable in viremic HIV infected (2012) (0)

This paper list is powered by the following services:

Other Resources About Bonaventura Clotet

en.wikipedia.org

What Schools Are Affiliated With Bonaventura Clotet?

Bonaventura Clotet is affiliated with the following schools:

Image Attributions

Image Source for Bonaventura Clotet